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Multiple Sclerosis (MS) is a frequently disabling neurological disease 
affecting young adults. The disease has been characterized by recurrent 
areas of focal inflammation (plaques) in the CNS giving rise to episodic 
neurological signs and symptoms. Helminth-associated immunoregulation 
has been investigated by the utilization of controlled hookworm infection in 
MS. Many studies have reported brain atrophy in patients with MS. This has 
been demonstrated as a major factor for physical and cognitive impairment 
in MS. In this thesis, I present our studies using immunomodulation, 
coordinate-Based Meta-Analysis (CBMA), Meta-Analysis of Networks 
(CBMAN), and Meta-Regression and voxel based morphometry (VBM) to 
study disease activity in MS. 
1) For a Randomized Double-Blinded Placebo-Controlled Trial, we 
examined the effect of hookworm treatment on white matter (WM) 
disease activity. 
2) Localised grey matter (GM) Atrophy in Multiple Sclerosis and 
Clinically Isolated Syndrome (CIS) was investigated by Coordinate-
Based Meta-Analysis, Meta-Analysis of Networks, and Meta-
Regression of Voxel-Based Morphometry Studies to reveal the 
significantly consistent regions and networks of GM atrophy in MS or 
CIS. 
3) A further VBM was conducted in the revealed clusters to investigate 
the difference in GM atrophy between hookworm and placebo arms 
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1.1 Multiple Sclerosis: Natural History 
Multiple Sclerosis (MS) is characterized as a chronic inflammatory disease 
affecting the Central Nervous System (CNS) that often has a relapsing 
course occurring at random intervals. Such inflammatory episodes, lasting 
from days to months usually, lead to injured myelin sheaths around nerve 
axons, damaged oligodendrocytes and, partial damage to neurons and 
neuronal processes.1–4 Pathologic evidence of acute as well as chronic 
inflammation is found in the lesions of the CNS. These lesions are multifocal 
and centered on draining veins of CNS. The timing of acute MS attacks can 
be caused by certain factors that have been identified as increasing or 
decreasing the likelihood of an attack in MS. Pregnancy (last trimester) can 
be considered as an example when the likelihood of experiencing an attack 
is decreased as compared to the risk during pre-pregnancy. This risk 
increases during 3-6 months postpartum.5 Estrogen level changes could be 
the probable explanation for these MS attacks. However, nonhormonal 
physiologic alterations occurring during pregnancy6 could also be 
responsible for the observed attack risk. Another factor that can be 
considered as an influence for risk of attack is infections that are non-
specific in nature7,8. Some authors have demonstrated that the timing of 
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some MS attacks could be related to vaccinations although the presented 
data is not convincing.9  
The cause of MS is not known. However, the involvement of immune-
mediated mechanisms is quite obvious and, most authors favor primary 
autoimmunity that is probably triggered by environmental events, as the 
essential pathophysiologic foundation for MS10. The pathologic 
characterization of MS involves demyelinating patches and gliosis causing 
formation of plaques, occurring in multifocal regions across the CNS white 
matter (WM).11 The selective susceptibility of specific CNS pathways to MS 
lesions is explained in the available literature but, the physiologic foundation 
of this irregular distribution is not construed properly. Previously, grey 
matter (GM) and the nerve axons were thought not to be affected however, 
substantial current research and evidence have highlighted the significance 
of axonal injury, specifically in case of acute active lesions, and also of 
demyelination of GM specially in the later stages of MS.12 Substantial 
evidence shows that autoreactive CD4+ and CD8+ T-lymphocytes (T-cells), 
macrophages, B-lymphocytes (B-cells) proliferate and travel across the 
blood-brain barrier(BBB) and, under the effect of proinflammatory cytokines 
and various cellular adhesion molecules, enter the CNS.13,14 These cells, 
that are activated, lead to injury of CNS tissue found in acute MS lesions. 
Chronic MS lesions are characterized by gliosis and by a variable degree 
of loss of axons. 
 
The 10-point expanded disability status scale (EDSS) is a widely used 
instrument for the quantification of the degree of disability in an MS patient 
- it was, initially developed in the 1950s and then adapted in several 
occasions.15 However, the EDSS is still quite complicated and subjective to 
score with poor test-retest reliability.16 Furthermore, it is nonlinear over its 
range as compared to the actual function level and it emphasizes mobility 
status more than other neurologic functions.15 In spite of these limitations, 
although many other scales have been introduced, MS clinical research and 
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practice continues to employ EDSS as the standard measure for disability.17 
Another multidimensional clinical outcome measure is the MS Functional 
Composite (MSFC). The MSFC comprises quantitative functional measures 
of three key clinical dimensions of MS: leg function/ambulation, arm/hand 
function, and cognitive function.16  
 
The first event of focal demyelination in the CNS is called as clinically 
isolated syndrome (CIS). About 60% of individuals with CIS suffer from a 
following relapse and a diagnosis of MS; this gets increased to 80% in case 
the baseline magnetic resonance image (MRI) demonstrates inflammatory 
lesions. Approximately, 85% of MS patients demonstrate a biphasic disease 
course that is marred by alternation in episodes of neurological disability 
and recovery, which is designated as relapsing remitting MS (RRMS).1  
Following this course, approximately 60-70% of RRMS patients transit into 
a secondary progressive disease course (SPMS), in 20-25 years, that is 
characterized by progression in neurological decline. Additionally, some of 
the MS patients (approximately 10%) exhibit a disease course of steady 
decline in neurological function that is not accompanied with recovery. They 
are classified as primary progressive MS (PPMS) patients. Some patients 
experience frequent relapses in early disease that leads to a rapidly 
evolving or highly active RRMS.18 There exists a period of diagnostic 
uncertainty regarding the transition from RRMS to SPMS. There might be 
several potential reasons for the delayed diagnosis of SPMS. The earliest 
indicators of SPMS may be subtle; these involve worsening of symptoms 
but little change occurs in the neurological examination. The clinician is also 
likely to be appropriately cautious in labeling a patient as having SPMS, 
given the lack of available evidence-based treatments for this condition and 
patients’ anxieties regarding its prognosis. In addition, a SPMS label may 





In accordance with a report by the MS International Federation20, the 
median prevalence of MS worldwide increased from 30 per 100,000 in 2008 
to 33 per 100,000 in the year 2013. This prevalence varies to a large extent 
among countries21 with the highest being in North America (140 per 
100,000) and Europe (108 per 100,000) and, it was found to be the lowest 
in sub-Saharan Africa (2.1 per 100,000) and east Asia (2.2 per 100,00).  
Specifically, various environmental risk factors, including infection with 
Epstein-Barr virus (EBV) 22, latitude23 and smoking24 have been put forward. 
The causative factors of MS are yet to be unraveled and there is no 
establishment of risk factors that could support prevention of the disease. 
Numerous systematic reviews and meta-analyses for MS environmental 
risk factors have been published.25 
Lazaros and colleagues26 conducted an umbrella review of systematic 
reviews and meta analyses of observational studies, from beginning to 
2014, for which they searched PubMed and included appropriate studies 
examining associations between environmental causative agents and MS. 
There was estimation of 95% prediction interval, further accounting for 
between-study heterogeneity and evaluating the uncertainty of the effect 
that can be expected in any new research, regarding that same 
association.27,28 With context to meta-analyses having continuous data, the 
estimate of effect was transformed to an odds ratio (OR) with an established 
formula.29  
The 3 systematic reviews included in the umbrella review investigated 
stress30, serum prolactin31 and socioeconomic status32 as MS risk factors. 
The umbrella review presented an evaluation of environmental risk factors 
for MS. The review considered 44 risk factors for an association with MS, 
that involved surgeries, infections and vaccinations and traumatic events, 
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comorbid diseases, exposure to toxic environmental agents and 
biochemical biomarkers. This review confirms 3 risk factors (anti-EBNA IgG 
seropositivity, smoking, infectious mononucleiosis) for the disease as 
supported by significant epidemiological credibility. Regarding consistency, 
smoking and EBV infection demonstrated association with MS without bias. 
Innumerable mechanisms have been put forward to describe the adverse 
effects of smoking on MS, having influence on immune system, 
demyelination, immune-modulatory effects and BBB disruption but, all such 
effects are still theoretical.33 Attention has been received by sun exposure 
and vitamin D as being counted as risk factors for MS. These might explain 
the latitudinal and geographical trends of MS incidence.23,25  
Genome wide association studies (GWAS) conducted for MS patients have 
resulted in the identification of over 100 genetic risk loci.34 
The aetiology of MS is complex involving genetic as well as environmental 
influences. The weight of evidence would favor a greater role for the 
environment over genetics. There is sufficient evidence for profound effect 
of the environment, with at least four or more directly contributing factors. 
The reported effect sizes are significantly greater as compared to any 
identified genetic factor.35 
The genetic predisposition suggests an explanation for MS cases within 
families. But this does not entirely explain the geographic variations in the 
frequency of MS and the risk variability occurring with migration. There is 
epidemiological support for the “hygiene hypothesis” but with provision for 
a specific role of EBV towards the development of risk of MS. Although EBV 
infection is one of many key features of MS epidemiology, the link between 
the virus and MS cannot clarify, on its own, the declined risk among 
migrants moving from high to low MS prevalence areas. This decline 
indicates that either the EBV strains in low risk areas are less liable to cause 
MS, or that other infectious or non-infectious factors have a modifying effect 
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on the response of host to EBV or otherwise contribute to determine the risk 
of MS.36 
There is a salient latitudinal gradient in the prevalence of MS, with 
exceptions in Mediterranean Europe and northern Scandinavia. This study 
has the purpose of evaluating the association between MS prevalence and 
latitude by meta-regression. The comprehensive review has confirmed a 
statistically significant positive association between MS prevalence and 
latitude globally. The exceptions are probably a result of genetic and 
behavioral-cultural variations.23 
Handel and colleagues24 conducted a meta-analysis wherein they 
performed a Medline search for the identification of researches investigating 
the risk of MS associated with cigarette smoking. 14 studies were included 
in the meta-analysis, the studies were analysed in a conservative as well as 
non-conservative manner. The prior way limited the analysis to studies 
where smoking was described prior to disease onset. The results of the 
meta-analysis demonstrate that smoking is associated with MS 
susceptibility. The research also analysed 4 studies reporting the risk of 
secondary progressive MS. It was found that the association was not 
statistically significant and, had considerable heterogeneity. 
The results demonstrated that there is an association between smoking and 
MS susceptibility but this effect on disease progression remained uncertain. 
Subsequent studies point to an effect of smoking on disease progression 
as well. For example Manouchehrinia and coworkers37 showed an 
association between smoking and disease progression which was 
confirmed by subsequent studies. 
Exposure to infant siblings has an influence on the age of MS onset. A study 
was conducted by Ponsonby and colleagues38 on a population of residents 
of Tasmania, Australia younger than 60 years with at least one grandparent 
who was born in Tasmania. The cases satisfying these criteria had 
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abnormalities in the MR images consistent with MS and clinically definite 
MS as per the neurological review.39 Interviews were held for the cases and 
controls between March 1999 and June 2001. The questionnaire intended 
to examine the environmental factors, particularly sun exposure, 
contributing towards the development of MS. It included questions 
regarding the number of siblings and their birthdates, whether their living 
place was the same, sun exposure in the past, history of cigarette smoking, 
medical history, whether the subject had been breastfed and 
sociodemographic features. Type of skin was determined using a 
spectrophotometer for the assessment of melanin density at the location of 
the upper inner arm. The type was considered ‘fair’ if the density of melanin 
was found to be less than 2%.40  
The authors found a strong statistically significant inverse association 
between exposure to infant siblings and MS and, these trends were 
sustained after adjusting for confounding factors.  
The finding that high exposure among controls reduces the risk for 
developing infectious mononucleosis as well as increased EBV IgG levels 
is debatable because the risk of infectious mononucleosis and high EBV 
IgG have been recognized to have a role in the etiology of MS.36,41 
Higher exposure to infant siblings in the first six years was related to a 
reduction in the risk of MS. This was probably due to alteration of patterns 
of childhood infection and associated immune responses. The study found 
that the increase in contact duration between the index child and a younger 
sibling aged less than 2 years in the first 6 years of life was associated with 
reduced MS risk. Among cases, higher contact with infants in early 
childhood had an association with delayed onset of MS.38 
According to the proposal put forward by Taylor and colleagues, smoking42 
and the hygiene hypothesis38 along with ultraviolet radiation exposure40 add 
up to be the environmental risk factors that have a significant effect on the 
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development of MS. Deficiency of vitamin D has a part to play in the 
causality of MS. It has been well established as a risk factor for MS with an 
association between low vitamin D and the significantly elevated risk of MS 
development.43  
MS has been found to be frequent in the developed areas of the world as 
compared to the ones that are developing.44 Considering these 
epidemiological observations, a variety of risk factors have been proposed 
that include Epstein-Barr virus, low vitamin D, smoking and sanitation.44,45 
However, the most enthralling is the inverse correlation between helminth 
infections and incidence of autoimmune disease.46 
Authenticating this hypothesis, studies that are longitudinal and involve 
translocating subjects for the evaluation of MS prevalence in the 
FrenchWest Indies over a duration of 20 years confirm that incidence of MS 
is increased in regions with significantly reduced parasite infections.47  
Being more specific, MS prevalence decreased significantly when a critical 
threshold (10%) of helminth (Trichuris trichura) infection was exceeded in 
any given population.48 The administration of anti-helminth drugs lead to 
elevated MS activity.49 This propounds the direct involvement of helminths 
in the suppression of autoimmune diseases and might be the protective 
environmental factor against MS development. 
1.3 Pathophysiology 
1.3.1 Inflammation and Demyelination 
MS is primarily an immune-mediated disease that involves the auto-
aggressive T-cells crossing the BBB imposing demyelination and axonal 
loss subsequently leading to disability. The formation of gadolinium-
enhancing lesions, due to an overt breach of BBB, is a crucial event in MS.50  
Recent developments in MS drug therapies highlight leukocyte passage 
across BBB in the disease pathophysiology. It has been reported by 
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histopathological studies that inactive MS lesions as well as normal 
appearing WM (NAWM) show abnormalities51. In addition, it has been 
demonstrated by MRI studies that structural alterations52,53 and BBB 
dysfunction54 might be heralding myelin damage and leukocyte infiltration.  
1.3.2 Neurodegeneration in MS 
This is an early part of the disease that undergoes self-perpetuation over 
time. The use of immunotherapy has been able to disclose considerable 
insights into the disease pathogenesis: for instance, while the reduction of 
relapses can postpone progression and disability55, it does not stop the 
disease evolution. This suggests that progressive worsening might require 
directly targeting the neurodegeneration and the processes causing it which 
arise without any association with immune attacks in the later disease 
stages. Therefore, while SPMS may not stand as a distinct phase arising as 
a direct consequence of RRMS, it could be the product of other 
pathophysiological mechanisms.56 
In recent years, the requirement of novel therapeutic strategies to 
specifically target neurodegeneration has been apparent, shifting the 
balance from neuroaxonal damage towards neuroprotection and/or 
regeneration. It would be inaccurate to consider neurodegeneration as a 
secondary phase of MS; it is an early allied process that is already 
proceeding since the time of diagnosis.57 
Damage of the axons is detectable even in MS lesions where axons are still 
myelinated58, and loss of axons can possibly provide the best correlate of 
neurological disability. Disturbances in axonal transport also promote 
progressive degeneration.59Disconnection of relapses with progression of 
disability is, however, challenging due to immunological involvement being 
implicated in the progression course. Epidemiological studies have 
demonstrated how to achieve delay in MS progression if the clinical EDSS 
score of 3.0 has not been reached yet; however, if that clinical threshold 
has been crossed, the disability is not as much responsive to any 
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management.60 This information supports the necessity to counteract 





Glial as well as endothelial cells can play a role in the promotion of recovery 
from stress and injury via the secretion of neurotrophic factors like brain-
derived neurotrophic factor (BDNF), nerve growth factor (NGF) and 
neurotrophin-3.62  
Furthermore, the importance of the maintenance of regulatory T-cell (Treg) 
populations has been highlighted by many studies for the prevention of 
autoimmune neuro-inflammatory damage in the EAE animal model of MS.63 
 
 
1.4 Course and Classification 
1.4.1 Classification  
The course of MS is quite diverse. Jean-Martin Charcot was the first person 
to describe a neurological triad consisting of intention tremor, nystagmus, 
scanning and staccato speech representative of MS, with the recognition of 
latent symptoms.  
In 1952, Douglas McAlpine and Nigel Compston64 produced simple line 
diagrams of the classic MS disease courses as shown in Figure 1 and, 
provided description to attacks, remission and chronic progression as a 






Figure 1: Adapted from 64; Line diagrams of the different courses of MS.  
 
The requirement for single common classifications became persuasive 
during the 1990s (the era of clinical trials), due to the unavailability of 
biological or imaging biomarkers. As a result of a survey issued in 1952 by 
the US Advisory Committee on Clinical Trials of New Agents in MS of the 
National Multiple Sclerosis Society (NMSS), Lublin and Reingold65 
classified four disease subtypes. These included relapsing–remitting (RR), 
secondary–progressive (SP), primary–progressive (PP) and progressive–
remitting (PR).  
However, different views have arisen recently with the arrival of imaging 
techniques. These include opinions like—confirmation of suspected RRMS 
by asymptomatic lesions observed on MR images following a single 
inflammatory event. Furthermore, new MRI lesions, with or without attacks, 
have the capability to predict future disability in progressive forms66 along 
with drug efficacy67,68, thereby indicating the importance of the need for 
identifying inflammatory activity in such patients.  
Attacks and new/enlarging T2-weighted lesions and/or new contrast-
enhancing lesions on MRI are now considered to be the markers of this 
disease activity. In 2014, the NMSS Advisory Committee, after revisions of 
previous definitions, published a novel classification along with new 





Attack, relapse, bout, 
exacerbation  
 
• Acute or subacute episodes of 
new or increasing neurologic 
dysfunction followed by full or 
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partial recovery, in the 
absence of fever or infection’’69 
• ‘‘Although a new attack should 
be documented by 
contemporaneous 
neurological examination, in 
the appropriate context, some 
historical events with 
symptoms and evolution 
characteristic for MS, but for 
which no objective 
neurological findings are 
documented, can provide 
reasonable evidence of a prior 
demyelinating event’’70 
• ‘‘30 days should separate the 
onset of the first event from the 
onset of a second event’’71 
Activity • Clinical: attacks 
• AND/OR imaging (MRI): 
occurrence of contrast-
enhancing T1 hyperintense or 
new or unequivocally enlarging 
T2 
hyperintense lesions.71 
Progression • Worsening for those solely in a 
progressive phase of the 
illness 
• Progressive disease: 







(fluctuations and phases of 
stability may occur) 
- Imaging (MRI): imaging 
measures of progression are 
not established or 
standardized and not (yet) 
useful as phenotype 
descriptors for individual 
patients.71 
Worsening • ‘‘Documented increase in 
neurologic 
dysfunction/disability as a 
result of relapses or 
progressive disease’’ 
• ‘‘Confirmed accumulation of 
disability would be defined by a 
worsening of EDSS that 
persists over x months’’71 
Clinically isolated syndrome • ‘‘The first clinical presentation 
of a disease that shows 
characteristics of inflammatory 
demyelination that could be 
MS, but has yet to fulfill criteria 
of dissemination in time’’65 
• ‘‘A CIS is, by definition, always 
isolated in time (i.e. 
monophasic). Clinically, it is 
usually also isolated in space 
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(i.e. monofocal) with signs 
indicating a lesion in the optic 
nerve (a common presentation 
in many reported CIS studies), 
spinal cord, brainstem or 
cerebellum, or (rarely) a 
cerebral hemisphere. 
However, some patients with a 
CIS have clinical evidence for 
dissemination in space (i.e. 
multifocal)’’72 
Benign and malignant MS ‘‘These terms, especially the term 
benign, which should always be a 
retrospective determination, are often 
misunderstood and misused. In a 
long-term disease like MS, the 
severity and activity of the disease 
can change significantly and 
unpredictably. We recommend that 
these terms be used with caution’’69 
 
Table 1: Adapted from73; Definitions of events or forms in MS. 
 
 
This classification defined CIS as a single attack. Radiologically Isolated 
syndrome (RIS) was defined in cases where incidental imaging findings, 
signifying inflammatory demyelination, were visualized in the lack of clinical 
signs or a history of attack and/or progression.65 Nonetheless, three classic 
disease forms were retained—RRMS, PPMS, SPMS—while asserting the 
inability of defining the ‘transition point’ where RRMS converts to SPMS. 
Among all the points, ‘‘the MS Phenotype Group believes that disease 
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activity detected by clinical relapses or imaging as well as progression of 
disability can be meaningful additional descriptors in either relapsing or 
progressive disease’’. This further led to two categorization levels: clinical 
phenotype (CIS, RRMS, PPMS, SPMS) and disease process (active or not; 
progressive or not). 
 
1.4.2 Course 
Most of the MS patients (85%) experience sequential acute clinical relapses 
(RRMS) at the start of the disease, ultimately experiencing progression 
(SPMS). The major predictive factor for recovery after an MS relapse is the 
length of time period of persistence of the episode, longer duration 
corresponding to worse stance.74 According to the literature, the proportion 
of patients who demonstrate incomplete recovery after their first episode 
range from 16% to 30%.3 Some data suggests that the recovery rates from 
relapses may be as low as 50%; therefore, it is essential to prevent relapses 
in order to prevent the risk of accumulating permanent disability.  
The development of a second clinical episode i.e. in a different location of 
the CNS leads to the diagnosis of clinically definite (CD) MS.39,71,75 The 
probability of the same is very high in the immediate repercussion of the 
initial episode and, diminishes thereafter.3,76,77This has been reported, for 
the placebo arms, in several randomized controlled trials recruiting CIS 
patients. The median time to experiencing the second attack in these 
studies was calculated to be ~2years. 
In recent years, radiologic evidence guides the diagnosis of CDMS 
demonstrating dissemination in space and time.70 According to the 2017 
revisions to the McDonald diagnostic criteria for MS, with a typical CIS, 
fulfillment of clinical or MRI criteria for DIS, and no better explanation for 
the clinical presentation, demonstration of CSF oligoclonal bands (OCBs) 
in the absence of atypical CSF findings permits a diagnosis of MS to be 
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made, even if the MRI findings on the baseline scan do not meet the 
criteria for DIT and in advance of either a second attack or MRI evidence 
of a new or active lesion on serial imaging.78 This recommendation allows 
the presence of CSF OCBs as a substitute for the requirement of fulfilment 
of DIT in this situation.79  
One large study, that enrolled 532 patients, reported a much longer median 
time for conversion to CDMS (7.1 years). This could partially be due to the 
utilization of ‘CDMS’ rather than ‘second attack’ that are not necessarily 
equivalent outcomes.39 The reason could also be the overrepresentation of 
optic neuritis patients (52%) and, the inclusion of large proportion (30%) of 
patients without the presentation of abnormalities on baseline brain MRI. 
None of the clinical parameters (eg. Onset age, gender, mono- or 
multifocality of initial symptoms or recovery degree since initial episode) 
have shown consistent influence on the likelihood of a patient experiencing 
a second clinical attack.76,80 
MRI abnormalities observed at clinical disease onset do impact this 
occurrence. Hence, the occurrence of and/or the number of MRI lesions 
have been steadily reported as a strong factor increasing the probability of 
a second neurologic episode within 1-3 years. 
There is an association of T2 lesion volume on brain MRI and the likelihood 
of a second attack, with higher volumes leading to greater risk.81 
Furthermore, researchers have demonstrated T1 gadolinium-enhancing 
lesions as a stronger predictor of development of a second episode.82,83  
The presence of new T2 lesions or gadolinium-enhancing lesions observed 
on a brain MRI performed 3 months following the baseline MRI84 or 12 
months following the initial episode forecast the occurrence of a second 




1.4.3 Clinical Features 
A person is suspected to have MS when there is presentation of a CIS. It 
can be mono- or polysymptomatic depending on the lesion (s) location. The 
most common presentations involve optic neuritis, spinal cord and 
brainstem syndromes. The less common presentations include cortical 
presentations like dominant parietal lobe syndromes. 
MS relapses are known to develop over hours to days followed by reaching 
a plateau and then recovering. Gross clinical recovery from relapses is often 
complete in early disease, however, they leave behind some damage. For 
instance, acute optic neuritis may result in contrast sensitivity, colour vision 
and depth perception abnormalities even after the recovery of visual acuity. 
There is loss of neuronal reserve and therefore, recovery from relapses 
becomes incomplete leading to accumulation of neurological deficits 
followed by sustained disability. 
For each clinical attack, roughly 10 ‘asymptomatic’ lesions are observed on 
MRI. A combination of location and lesion volume give rise to symptoms – 
a small lesion in an eloquent region is likely to cause symptoms. Many more 
lesions are visible at the microscopic level along with lesions in the deep 
and cortical GM, along with macroscopic lesions or those visible on MRI. 
The development of SPMS takes place 10-15 years after the onset of 
RRMS with a steady evolution from distinguished relapses to slowly 
progressive disease. Instead of a discrete transition between the disease 
categories, there is occurrence of relapses on a background of progression 
before progression taking over. The progressive brain atrophy and impaired 
cognition in early stages of the disease signify that clinical onset marks the 
initiation of neurodegeneration. 
5%-15% of cases present with PPMS, demonstrating gradual progressive 
disability accrual involving one dominant neuronal system. Patients 
commonly present with a progressive spastic paraparesis, but sensory 
ataxia, cerebellar ataxia; progressive visual and cognitive failure are well-
described PPMS variants.  
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Pediatric MS is rarer as compared to adult onset disease, with a highest 
reported incidence of 2.9/100,000.85 It is diagnosed on the basis of repeated 
demyelination episodes separated by time and space. It has been found to 
be challenging to distinguish paediatric MS from acute disseminated 
encephalomyelitis, due to pediatric MS being multifocal at onset. Physical 
recovery in this form of disease is seen to be more complete despite relapse 
rates being higher.  
Thus, MS can be considered as a disease existing within a spectrum 
ranging from relapsing (‘inflammatory dominant’) to progressive 
(‘neurodegeneration dominant’), in keeping with the 2013 revisions to the 
clinical course of MS.69 
 
1.4.3.1 Relapses 
These are referred to as acute attacks, flare-ups or exacerbations, involving 
acute or sudden onset of focal neurological disturbances. Examples of 
typical MS relapses include blurred vision in one eye (optic neuritis), 
weakness of a body part (motor system relapse), persistent tingling or 
numbness of a body part (sensory system relapse), or loss of coordination 
(cerebellar system relapse). 
Relapses are a characteristic feature of the RRMS subtype. Most patients 
demonstrate a recovery within six weeks, although improvements can take 
months for some. Recovery can comprise of a complete return to baseline, 
partial return or no improvement; with some degree of improvement being 
typical early in the disease. It is essential for deficits to persist for a minimum 
of 24 hours for it to be considered a relapse.  
New abnormalities lasting for a few seconds to minutes, like paroxysmal 
attacks (stereotypic neurologic deficits lasting less than a minute, occurring 
multiple times a day) or (Lhermitte’s sign (tingling sensation radiating down 
the neck, arms or back on neck flexion) are also considered as relapses in 
case they occur repeatedly over several weeks.86 
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Sequential relapses are considered discrete only in case they occur 30 days 
apart with a month of clinical stability in between. Clinical relapses are 
known to always change a patient’s condition but don’t always demonstrate 
changes on neurological examination. Greatest deficit in a relapse typically 
develops over a period of several days but can develop much faster over 
hours or minutes or gradually over weeks.  
Factors such as pH, temperature or electrolyte balance can cause 
temporary disruption of nerve conduction resulting in neurologic 
abnormality. Hence, it is important to differentiate between relapse and 
pseudo-exacerbation, latter being a neurologic deterioration associated 
with a physiologic change like fever or infection. Deficits due to pseudo-
exacerbation disappear after correction of the precipitating factor. 
About 85% of MS patients begin with relapsing-remitting disease.1 
Relapses in MS can either involve a single neural system, as in optic 
neuritis, or several anatomically different systems, as in combined motor 
and sensory problems. The former is more likely and common in the first 
MS relapse. 
Relapses involving sensory, visual or brainstem systems demonstrate a 
better prognosis as compared to those with the involvement of motor, 
cerebellar or sphincter systems. A low rate of relapse, in the first 2 years, 
accompanied with excellent recovery indicates a better prognosis as 
compared to a high relapse rate accompanied with poor recovery. With a 
disease duration of more than equal to five years, an increased rate of 
relapses, poly-regional relapses involving multiple systems and incomplete 
recovery from relapses signify a worse prognosis.87 
 
1.4.3.2 Progression 
Contradictory to the relapsing MS form, progressive MS is characterized by 
slow deterioration and increase in neurologic deficits. Once relapsing 
patients enter a progressive disease phase, they either discontinue with 
experiencing relapses or continue to experience exacerbations 
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superimposed on gradual worsening. Documenting a progressive course 
necessitates at least six months of observation. Slow deterioration is the 
principal defining feature of progressive MS, occurring independently of 
acute relapses without reflecting residual deficits from relapses.86 
Progressive MS is a more severe disease form as compared to benign or 
relapsing-remitting MS and, possesses a worse prognosis.86 
1.5 MRI in MS 
There has been growing involvement of MRI techniques in the evaluation 
of MS. The roles include initial evaluation of patients suspected of having 
the disease to secure or reject the diagnosis of MS88,89. It has also been 
used as a prognostic tool at first presentation of symptoms with extreme 
probability of acute inflammatory CNS demyelination, in provision of primary 
outcome measures for phase I/II clinical trials and as a source of critical 
supportive outcome measures in phase III trials of MS therapeutics.  
The value of MRI in MS stems largely from its extreme sensitivity to 
alterations in regional proton relaxation times occurring with processes that 
bring about change in tissue water content and constraints on hydrogen 
molecule motion, specifically those linked to tissue-bound and free water 
molecules. However, the current MRI techniques and methodology 
continue to be insensitive towards the detection of underlying disease 
processes that lead to these alterations. As a result, there is a limit on the 
specificity of MRI signals and plentiful overinterpretations of imaging results 
to imply specific changes in histopathologic tissue alterations.  
Many lesion patterns and distributions observed on conventional and even 
advanced MRI neither reflect a histopathology nor are disease specific. 
Therefore, a broad differential diagnosis persists in case MRI is considered 
isolated from the clinical history, laboratory investigations and physical and 
neurologic findings.  
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However, understanding the sequence of events associated with the 
formation of MRI-visible lesions, and the characteristic topography of 
lesions in the brainstem, cerebrum and spinal cord assist in the 
determination of the likelihood of MS in a patient and, provide reasonable 
markers that can be utilized for the inference of therapeutic effects on the 
developing underlying disease process.  
Since the introduction of McDonald diagnostic criteria for MS in 2001 up till 
the 2017 revisions, they are based on the size, number and location of brain 
and spinal cord lesions believed to be typical of the disease.90  
An update to the standardized approach of imaging MS patients that has 
been developed by the Consortium of MS Centers provides the minimum 
required sequence to support in the diagnosis and monitoring of MS that 
can be performed on variable clinical scanners. It involves 3D T1-weighted, 
3D T2-weighted, 3D T2 FLAIR and post-single-dose gadolinium-enhanced 
T1-weighted imaging, all with a non-gapped section thickness of <=3mm, 
and a DWI sequence of <=5mm section thickness.  
The breakdown of BBB can be detected by gadolinium contrast. It occurs 
with the development of new lesions and reactivation of old lesions. The 
enhancement has an average duration of 3 weeks for individual brain 
lesions,91 with most enhancing for 2-6 weeks.  
MS brain lesions rarely enhance persistently for more than 3 months with 
single-dose gadolinium. Mostly, all newly enhancing lesions will lead to 
residual T2 hyperintense lesion, following the resolution of the 
enhancement.92 The detection of new or enlarging T2 lesions in comparison 
to a previous scan can indicate new inflammatory activity even in the 
absence of contrast enhancement.  
Current conventional MRI techniques consist of several series of image 
acquisitions based on pulse sequences employed to provide optimal tissue 
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contrast for the purpose of routine clinical diagnostic work. These have 
continued to be the foundation for addressing disease activity in patients 
recruited in clinical trials.88  
1.5.1 MS lesions 
An MS lesion is defined as a focal hyperintense region on T2-weighted (T2, 
FLAIR or similar) or a proton-density (PD) sequence. The shape of 
characteristic MS lesions is round to ovoid ranging from a diameter of a few 
millimetres to more than one or two centimetres. In addition, the lesions 
should be a minimum of 3mm in their long axis to fulfill the diagnostic 
criteria; however, the topography should also be considered.  
Lesions should be visible on at least two consecutive slices in order to 
exclude small hyperintensities or artefacts. However, in higher slice 
thickness acquisitions, smaller lesions may be detectable on a single slice. 
MS lesions are typical of development in both hemispheres with mildly 
asymmetric distribution in initial stages. They might have an occurrence in 
any region of CNS, comparative to disorders causing WM lesions but have 
a tendency to occur in specific areas of WM, like the corpus callosum, 
periventricular and juxtacortical WM, infratentorial regions (specifically the 
pons and the cerebellum) and spinal cord (preferably the cervical 
segment).90  
1.5.2 MRI techniques 
Since the dawn of the MRI era, it was quite evident that due to its sensitivity 
in revealing focal WM abnormalities, it has the capability to become a 
valuable tool for the assessment of MS. This has been the case in the 
diagnostic workup of MS, while also playing a major role in the elucidation 
of mechanisms underlying disease progression as well as in the monitoring 
of accumulation of abnormal features underlying disability. For the 
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development of imaging strategies that can provide an accurate estimate of 
the extent of disease-related damage, considerable effort has been 
dedicated.  
Guidelines have been established for the integration of magnetic resonance 
findings into diagnosis of patients presenting with CIS suggestive of MS,70 
and specific acquisition protocols have been put forward for the longitudinal 
monitoring of change in patients with clinically definite MS.93  
Furthermore, regarding MS research, conventional MRI has been 
substantially enhanced by quantitative MR techniques that demonstrate 
greater sensitivity and specificity for the assessment of heterogeneous 
pathological substrates of the disease. This is not only in context of focal 
T2-visible lesions but also in normal appearing WM (NAWM) as well as GM. 
More recently, novel imaging techniques that are capable of gauging 
pathological processes in relation with the disease which had been 
neglected previously (eg iron deposition and perfusion abnormalities) and 
the advent of high and ultra-high field magnets have facilitated the provision 
of further understanding of the pathobiological features of MS.94  
1.5.2.1 MRI as a diagnostic tool in MS 
Various MRI platforms with different magnetic field strengths are utilized at 
present for diagnosing MS, and the most frequently applied magnet 
strengths are 1.5 Tesla (1.5T) or 3T. 3T magnetic strength has been shown 
to have increased sensitivity for detecting MS lesions due to improved 
signal-to-noise ratio and resolution;95 however, utilization of 3T MRI as 
compared to 1.5T MRI has not been demonstrated to facilitate early MS 
diagnosis.96 Still, 3T MRI is considered preferable in the current MAGNIMS 
criteria, with inclusion of both field strengths in the recommendations.97,98 
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Inspite of the significant improvements in the most recent changes made to 
the McDonald criteria, a few aspects have elicited criticism. Relevantly, 
simplification of the criteria has led to it being less restrictive, that might 
further lead to an overdiagnosis of MS.98,99 Additionally, collection and 
interpretation of CSF is not required in accordance with the most recent 
guidelines. Therefore, prudence is needed when McDonald criteria are 
employed for differentiation of MS from other potential CNS pathologies; 
however, in case of uncertain presentations, CSF samples might increase 
diagnostic specificity. 
Susceptibility-weighted imaging (SWI) has been suggested to be a 
sequence for better diagnostic values. SWI at 7T has demonstrated 
remarkable detection of central veins.100,101 According to the literature, 
periventricular inflammatory lesions can be depicted with diagnostic 
accuracy, by using FLAIR in combination with T2* at 3T. After validation, 
this presents to be a highly useful tool in clinic for differentiation between 
MS and other WM pathology.102 Such novel measures have the capability 
to facilitate the differential diagnosis of MS and support the representation 
of demyelinating lesions associated with MS. 
Generally, the use of MRI has become a well-established tool for diagnostic 
purposes and facilitates the early diagnosis of MS. This offers the 
opportunity to initiate immune-modulatory treatment as soon as possible. 
Yet different pathologies need to be assessed with prudence and excluded 
before a patient is committed to long-term treatment. In summary, the 
McDonald criteria have a high sensitivity but are not as specific for the MS 




1.5.2.2 MRI as a prognostic tool in MS 
An important role is played by MR imaging for the prognosis of disease 
development and monitoring of disease progression. Multiple studies have 
focused specifically on the predictive value of T2-hyperintense lesions, T1-
hypointense lesions, referred to as black holes (BH), along with implication 
of overall atrophy observed on MRI with the progression of disease. These 
individual modalities have been employed for predicting the development of 
MS from CIS, RIS and for the general prediction of long-term disability.103  
 
1.5.2.3 Lesion Evolution 
On conventional MRI, new lesions arising in earlier NAWM are almost 
always distinguished by a nodular area of Gd-enhancement on T1-weighted 
images.104 This is nearly customarily associated with a hyperintense lesion 
in the same location on T2-weighted images.105 Approximately 65% of the 
larger enhancements correspond to hypointense lesions observed on non-
contrast T1 MRI106. Most enhancements fade away over a period of 4-6 
weeks, and 50% of the hypointensities experience spontaneous resolution 
within 4 weeks. Return to the T1-isointense state or mild T1 hypointensity 
might be an indication of extensive or partial remyelination.107  
Hypothetically more aggressive lesions have a ring-like propagation of 
enhancement over a few weeks or longer before the enhancement begins 
to fade, have a central spherical hypointensity on T1-weighted images, have 
more complicated appearances on T2-weighted images and are persistent 
over time. An incomplete enhancement ring (“open ring sign”), open where 
the lesion abuts GM, characterizes MS.108 There can be an observation of 
a complete ring specifically in case lesions are confined to WM. Vigilant 
inspection of regions around some of the larger T1-hypointense lesions 
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contracting over time signifies this apparent repair to be at the expense of 
surrounding tissue loss. Along with the center of such lesions likely 
undergoing gliosis and contraction, there is occurrence of regional 
ventricular enlargement and loss of cortical volume directed toward the 
lesion.  
Even though T1-hypointense lesion evolution has profound link with 
enhancements, the relationship might be more complex. Frequency of 
enhancement is age-dependent, being lesser among older MS patients of 
all disease subtypes.109 Still, hypointense lesions are more commonly 
observed in case of longer disease duration and among progressive 
disease subtypes. The conflicting behaviour of these apparently inter-
related MRI metrics might suggest that whereas some hypointense lesions 
result directly from new inflammatory events that are readily monitored by 
enhancements on MRI, other hypointense lesions may evolve in a different 
way. 
With regards to advanced imaging, monitoring of lesion evolution is more 
complex. Newly-enhanced lesions that occur within previously conventional 
MRI-defined NAWM provide informative regions for retrospective scrutiny 
for change that occurs before lesion evolution on conventional MRI. 
Retrospective analyses suggest that regional abnormalities in 
magnetization transfer imaging (MTR) develop in NAWM months before the 
enhancement is visible on conventional MRI.110 However, these changes 
unfortunately have not shown enough robustness for prospective use.  
MRI findings, as an outcome measure, are used by most clinical trials for 
the investigation of treatment efficacy. Number and size of T2-hyperintense 
lesions and contrast-enhanced T1-weighted lesions are focused on. The 
effect of treatment on lesion burden was evaluated in treatment studies by 
a recently conducted meta-analysis of various trials. It demonstrated that 
treatment effects on MRI lesions over short time periods (6-9 months) also 
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have the ability to predict relapses over longer periods of follow-up.111 The 
overall analysis of these 31 studies showed that there is association 
between new or enlarging T2-hyperintense lesions and contrast-enhanced 
T1-hypointense lesions and, number of relapses. Thus, the use of MRI was 
proposed as a primary endpoint for treatment trials. 
MRI has been employed in many observational studies for identification of 
patients at high risk for treatment failure as determined by clinical disease 
progression. 
Three or more new T2 lesions or new enhanced lesions within the first 2 
years foretold worse disease progression, and follow-up after 15 years 
provided confirmation of these findings.112 In the presence of more effective 
therapeutic options, achievement of multi-metric disease stability or ‘no 
evidence of disease activity’ (NEDA) has been emphasized. The definition 
of NEDA has basis in the absence of new disease activity on MRI and, in 
the absence of relapses and disability. It has been used for the assessment 
of positive treatment response for RRMS patients after 2 years.113 The 
original criteria are now referred to as NEDA3, given the latest proposed 
expansion to NEDA4, involving brain atrophy and suggested to be an 
improved metric for disease stability.114 It needs to be considered that 
NEDA is a developing measure and, there are contradictory studies 
concerning the prognostic potential of NEDA for the purpose of long-term 
disease stability.115 Nevertheless, the availability of new treatment 
modalities offers a more aggressive ‘treatment to target’ approach and 
might provide a prospect to achieve NEDA. The existence of new activity 
on MRI is a crucial marker for the clinical setting, which can be inferred as 
a suboptimal treatment response and a change of treatment needs to be 
considered on a case-by-case basis. There is unavailability of guidelines 
regarding the timing of obtaining MR images for best objective assessment.  
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In RRMS patients on DMT with long disease durations, who are clinically 
and radiographically stable or patients with longstanding progressive MS, 
further imaging should be customized according to individual 
circumstances. In addition, younger patients with progressive disease 
should undergo MR imaging frequently. There might be occurrence of new 
lesions in patients with progressive MS and adjusting therapy can be 
considered. Patients with untreated CIS should be scanned every 1–3 
months for the initial 6 months and, in case stable repeating MRIs every 6–
12 months is recommended, if possible, unless there is occurrence of new 
clinical symptoms. Largely, these imaging recommendations permit close 
monitoring in order to assess disease activity and treatment response for 
the achievement of NEDA.103  
1.6 Gray Matter Pathology in MS 
1.6.1 Gray Matter Pathology and Diagnosis of MS 
There has been clear demonstration of cortical lesions occurring in all MS 
phenotypes through neuroimaging studies116, not only in the late disease 
stages but also early on. Indeed, cortical lesions have been visualized prior 
to the development of WM lesions117, as well as in radiologically isolated 
syndrome (RIS)118 and CIS116. As with cortical demyelination, GM atrophy 
can be detected very early in the disease and accelerates over time119.  
Similar to cortical lesions, GM atrophy measures are apparently predictive; 
Calabrese and colleagues120 showed that in comparison to CIS patients 
meeting the DIS criteria, CIS patients and atrophy of either the superior 
frontal gyrus, cerebellum or thalamus had double the risk of conversion to 
clinically definite MS. However, it should be kept in mind that the predictive 
power of GM atrophy may be less than GM lesions in CIS.  
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1.6.2 Gray Matter Atrophy in MS 
In addition to the well-known local inflammatory and demyelinating lesions 
that are routinely observed in the WM, MS is also associated with 
degeneration and consequent GM volume loss that is often referred to as 
GM atrophy.  
Brain GM atrophy is typically measured in vivo using standard 3D T1-
weighted images acquired by MRI, and automated analysis methods. 
Previous studies have demonstrated decreased volume of subcortical GM 
structures as well as reduced volume or thickness of cortical regions121.  
1.6.3 Evolution of GM atrophy 
It is not very clear which particular brain regions are most likely to develop 
GM atrophy in the early phase of the disease, whether the atrophic process 
is primary or secondary, or to what extent its evolution is distinct between 
disease types122–124.  
Partially, this can arise from methodological issues, like unknown 
sensitivities of different measurement methods to atrophy in different GM 
regions. The simultaneous evolution of focal lesions and other pathological 
changes, along with the varying and partly unknown effects of different 
treatments on GM atrophy, further obfuscate the understanding of natural 
evolution of GM in MS. 
In relapse-onset MS, GM atrophy has been observed already in the earliest 
phases of the disease122,125. Moreover, there might be a difference in GM 
atrophy between the disease types123,126, as well as between patients with 
and without evidence of disease activity127. Scientific literature has some 
evidence of early and articulate GM atrophy in specific regions: for example, 
the involvement of the cingulate cortex was found to occur throughout the 
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disease course, in PPMS128. Also, significant GM volume loss occurred in 
the right precuneus in RRMS patients with progressive disability129. 
Moreover, atrophy of specific DGM structures, specifically the thalamus, 
also occurs in MS patients151–153. Atrophy of the thalamus apparently occurs 
early and prominently, worse in men, and has an association with cognitive 
decline132. However, it remains unclear as to what extent these 
observations could be biased by the size and partially limited contrast with 
the neighboring WM of the thalamus. In general, more research is required 
for the validation of the dynamic alterations and anatomical patterns 
observed in previous studies.133 
 
1.7.4 Brain atrophy and the risk of disease progression 
Brain atrophy is detected in early disease stages, even in stages without 
clinical symptoms.134,135 The rate of brain atrophy is greater in CIS patients 
that progresses to MS when compared with patients who show no 
worsening over the disease course. This has an impact on the early 
prognosis of the disease136.  
A sub-analysis from the ETOMS study (which dealt with the assessment of 
the efficacy of subcutaneous interferon beta 1-a in CIS patients) 
demonstrated a significant difference in mean annual percentage brain 
volume change (PBVC) between patients who had disease progression 
versus those who did not 137.  
An observational study performed by Pérez-Miralles et al.138 reported 
similar findings showing a greater decrease of PBVC in 176 CIS patients 
who progressed to MS when compared to those who did not progress.  
These findings established a prognostic role for brain atrophy and 
conversion to MS in patients who had first demyelinating event. 
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The study by Di Filippo et al.139 demonstrated the prognostic role of brain 
atrophy and the risk of progression to MS following a first clinical event. In 
the concerned studies, the CIS patients that progressed to MS during a 
follow-up of 6 years had an atrophy rate of 0.5% vs -0.2% of those who did 
not; thereby producing this as an important prognostic factor for conversion 
to MS.  
Steenwijk and colleagues140 performed a study looking particularly at 
cortical atrophy in patients with long-standing MS, that suggested largely 
non-random patterns. A commonly held view of MS, previously, involved a 
multifocal and multi-phasic immune-mediated WM inflammatory 
demyelinating disorder. Indeed, the suppression of such a process has 
reinforced the progress in DMT till date. It is now quite clear that 
demyelinating lesions are possibly as extensive in GM as they are in WM, 
and there is substantial neuro-axonal loss in NAWM, WM lesions, cortical 
GM and deep GM. It is also unambiguous that GM pathology is present in 
early RRMS that increases with time.   
Brain tissue loss does not have a uniform occurrence; in progressive MS, it 
is most apparent in the GM, having an effect on some cortical and DGM 
regions more than others122–124. In vivo, significant associations of GM 
atrophy with physical disability, cognitive impairment and progressive MS 
have been identified by MRI-clinical correlation studies. There are 
compelling reasons to make an attempt in order to better understand the 
GM atrophy mechanisms and the further reflected neurodegenerative 
process.  
Steenwijk and coworkers140 reported on their work observing patterns of 
cortical GM atrophy in MS. The authors employed source-based 
morphometry (SBM), an evolved voxel-based morphometry (VBM) 
approach. Both SBM as well as VBM support the identification of regional 
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disease effects on MRI scans without the need for a priori-defined regions 
of interest. 
Furthermore, VBM looks for regions consistently different between groups 
and, SBM looks for regions where MRI features tend to differ together, 
further determining how they are weighed in different groups. Practically, 
this further means that SBM might have greater sensitivity towards 
distributed but connected regional disease effects, as occurs in case of a 
damaged brain network.  
In consistency with previous VBM studies, the SBM analysis confirms that 
GM atrophy does not have an even occurrence throughout the cortex. 
However, it also shows that underlying this are overlapping regional 
‘patterns’ of non-random cortical atrophy. Steenwijk et al. hypothesize that 
these patterns of atrophy are initiated by the tract-mediated effects of WM 
lesions on cortical ‘hubs’ (i.e. cortical regions that are located centrally in 
structural networks), with subsequent network-mediated (trans-synaptic) 
degeneration further extending from these hubs.  
The literature supports such a network-based interpretation141, but does not 
necessarily exclude alternative explanations.  
Steenwijk and colleagues140 have discovered an essential new feature of 
cortical GM atrophy in MS; that it not only occurs in some cortical regions 
more than others but also that regions of predilection can be linked in a non-
random way. These findings could have several explanations, and their 
elucidation would be worthwhile provided the clinical importance of GM 
atrophy in MS, and the potential to discover novel mechanisms for rationally 




1.7.5 Review of measurement techniques 
There has been development of various methods for the measurement of 
anatomical changes in the brain. Some of the measurement techniques 
produce single-subject measurements while others, such as VBM, provide 
statistical tests that are group-based.  
In this section, the predominant interest is the application of brain GM 
atrophy measures between two different groups of MS patients from the 
WIRMS clinical trial142 (HW and Placebo). This VBM analysis involves the 
measurement of GM density in a priori ROI derived from the coordinate-
based meta-analysis143 results. 
1.7.6 Group-level analysis methods 
VBM is an extension of voxel-wise segmentation-based techniques such as 
SIENAX or SPM, that comprise of the transformation of GM segmentation 
maps into a common space. One can then continue with the investigation 
of differences between groups and correlations with other variables for each 
voxel or vertex in the common space separately (followed by appropriate 
corrections for multiple testing). 
The key strength of such methods is that they allow the study of anatomical 
patterns undergoing atrophy without any a priori selection of ROIs. 
Prominent regions and anatomical patterns can, therefore, be detected from 
the data.  
The statistical method employed in brain morphometric analyses is the 
general linear model (GLM). This is utilized due to its ability to incorporate 
a multitude of effects.144 
48 
 
1.7.6.1 General Linear Model 
The General Linear Model (GLM) arises from regression and correlational 
methods and can be construed as a general multiple regression model.  
The GLM has been successfully used in the analysis of brain structures 
because of its flexibility to handle both categorical (e.g. groups of subjects), 
and continuous variables (e.g. test scores). It can be used to examine 
regions of interest (ROI) from which various morphometric markers can be 
extracted, but it has been most successful in whole brain analysis using a 
voxel based approach for GM.  
The GLM is employed for modelling and statistical hypothesis testing in 
almost all areas of neuroimaging. This is due to its great flexibility - it can 
be used to analyze within-subject as well as between-subject data. 
 
1.7.6.1.1  Linear Modelling  
Regarding its foundation, the GLM is a way to model an observed signal in 
terms of one or more explanatory variables, also known as regressors. 
Signal here could direct towards the series of measurements associated 
with individuals in a group, e.g., the cortical thickness in different patients at 
a given anatomical location. The GLM makes an attempt for the explanation 
of this series of measurements in terms of one or more regressors (also 
called explanatory variables), which consist of series of values that 
represent patterns that are expected to be found in the measured signal. 
 
The GLM is fundamentally a linear model, which means that it has the ability 
to scale the regressors and add them together in order to best explain the 
data. Many GLMs involve more complex relationships with time or subject 
ID. The linearity depends on how the regressors can be combined together 
to explain the data. 
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The simplest GLM is the one modelled with a single regressor; here the 
model only contains one parameter that is fit, which is the scaling value for 
this regressor; this scaling is β. This has a close relation to Pearson’s 
correlation, as correlation provides one way for measuring the similarity of 
two signals (the regressor and the data in this case) whereas the GLM 
models how well one signal (the regressor) can fit another (the data).  
To determine the best value of the scaling parameter, the GLM examines 
the difference between the data and the scaled regressor (the fitted model). 
This difference is known as the residual error, or more concisely just as the 
residuals.  
In equation form, the GLM can be expressed as: 
Y = X β + ε, where Y represents the data, X represents the regressor, β 
represents the scaling parameter and ε represents the residual errors.  
In the case of working with neuroimaging data, there would be a separate 
GLM for each location in an image - that is, for a particular voxel location 
there is extraction of one value from each subject and, analysis of these 
values is performed in one GLM. This is then repeated for every voxel 
location, running a separate GLM, but (typically) using the same regressors 
for all these GLMs as it is the dependent variable that changes.  
Altering the scaling parameter will change the model fit and hence the 
residuals, and the best fit is the one that corresponds to the smallest 
residual9s (quantified by the sum of squared values). This is known as 
minimising the residuals (or finding the least squared error) and can be 
performed using the GLM. The fitted or estimated parameter value is often 
denoted as B̂ and represents a value that is estimated or calculated from 
the noisy data. This is in contrast to β (without the hat), which usually 
represents an ideal or theoretical value. 
When using the GLM it is not only the β value that we are often interested 
in, but also the uncertainty surrounding its estimation: we need to know both 
in order to perform any statistical testing. The uncertainty in the value of any 
given B̂ is affected by the noise (i.e., the size of the residuals) but also, in 
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the case of multiple regressors, by whether there is a correlation between 
individual regressors.145 
 
1.8 Focus of interest 
In this study, we examine the new disease activity by means of alterations 
in WM lesions for patients recruited in the WIRMS clinical trial, as can be 
seen in chapter 3. Further, as can be seen in chapter 4, we conducted 
coordinate-based meta-analysis, meta-analysis of networks, and meta-
regression to summarize the evidence from VBM of regional GM changes 
in patients with MS and CIS, and whether these measured changes are 
relatable to clinical features. The eight significant clusters, that were the 
result of the meta-analysis, were used as ROI for VBM to analyze GM 
atrophy in placebo versus hookworm-treated patients, in the change from 
the initial visit to final visit (chapter 5). This is followed by the general 






This chapter mentions the methods used in the included research.  
2.1 WIRMS 
2.1.1 Cohort 
The cohort in the WIRMS study involved adults with relapsing MS. 
2.1.2 MRI acquisition 
Acquired images were: 3D axial T1 weighted fast spoiled gradient echo 
(1×1×1mm isotropic, 256×256×156 matrix), post gadolinium (Gadovist, 
standard dose; Gd) acquisition of axial T2 weighted fast spin echo, and 
axial T2 weighted fluid attenuated inversion recovery images 
(0.98×0.98×3mm, matrix 256×256×60) which achieved about 13 minutes’ 
delay between Gd injection and post Gd axial T1 weighted spin echo. 
2.1.3. Reproducibility Analysis 
Bland-Altman plot is constructed to describe agreement between two 
quantitative measurements by constructing limits of agreement. These 
statistical limits are calculated by using the mean and the standard deviation 
(s) of the differences between two measurements. The graph is a scatter 
plot XY, where the Y-axis shows the difference between the two paired 
measurements (A-B) and the X-axis represents the average of these 
measures ((A+B)/2).  
For the purpose of assessing the reproducibility of the MRI outcomes two 
people independently measured: (i) newly enhancing T1 lesions and (ii) 
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sum of new and enlarging T2-weighted lesions. Bland Altman analysis was 
then performed. The Bland and Altman analysis is a way to evaluate a bias 
between the mean differences, and to estimate an agreement interval, 
within which 95% of the differences of the second method, compared to the 
first one, fall.146  
2.1.4 T2 lesion load at baseline 
The total number of T2/FLAIR lesions were counted on the initial MRI 
(Figure 2A) for all patients. This was done to analyze, after the unblinding, 
whether the 2 arms were matched for T2-weighted lesions at baseline and 
to check that the patients were not atypical. 
2.1.5 Contrast-enhancing lesions 
The number of contrast (gadolinium) enhancing lesions were observed on 
T1 contrast-enhancing MRI for each patient at all visits (Figure 2B). This 
was done to analyze whether the 2 arms were matched for contrast-
enhancing lesions at baseline. 
2.1.6 Newly enhancing T1 lesions 
Newly enhancing old lesion has been characterized as a lesion that is 
contrast-enhancing on a visit and was visible on the previous visit but was 
not contrast-enhancing (Figure 2 C, D, E). The number of newly enhancing 
lesions on T1-weighted MRI have been counted on all visits.  
T1-weighted contrast-enhancing images were acquired post-Gadolinium 
and for image analysis they were registered to the equivalent image from 
the previous visit. The images were investigated for each MR slice and the 
two MR images automatically swapped periodically to highlight (newly 
enhancing lesions appear to ‘flash’ as images are swapped) newly 
enhancing lesions on the following visit, which were observed and counted.  
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The number of newly enhancing lesions on T1-weighted MRI were counted 
on all visits. 
The non-enhancing T1 lesions always have corresponding hyperintense 
lesions on FLAIR/T2. Newly enhancing lesions are characterized as those 
already visible on FLAIR in the previous visit MRI and are newly enhancing 
on T1 Gd+ MRI. Therefore, if we consider a patient, an 
‘old newly enhancing lesion’ must: not have been enhancing on T1 but 
should have been visible on the Flair/T2 at the previous visit. 
2.1.7 New T2 lesions  
The number of new lesions on FLAIR has been counted comparing initial 
with final MRI, following rigid registration, for all patients. T2 spin echo 
images were registered using rigid registration and visualized slice by slice 
with automated switching between the 2 images. This efficiently highlighted 
new and enlarging lesions for observation.  
 
A new lesion has been characterized as the one visible on the final MRI and 
not on first MRI. Lesions that were simultaneously new/enlarged and 
enhancing were only counted/considered once. T2 spin-echo or FLAIR 
images were registered using rigid registration and visualized slice by slice 
accompanied with automated switching between the 2 images. This 
enabled efficient emphasis of new and enlarging lesions. (Figure 3A, B). 
2.1.8 Enlarging T2 lesions 
The enlarging lesions on FLAIR were counted comparing the initial MRI with 
final MRI. The lesions on first MRI were marked as Regions of Interest 
(ROIs) and an enlarging lesion was characterized as the one that had 
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Figure 2: (A) Demonstration of lesion (marked with ROI) on FLAIR; (B) 
Demonstration of contrast-enhancing lesion (marked with ROI) on T1-
weighted Gd+ MRI (C) patient xx V9 FLAIR MRI (marked with arrow) (D) 







Figure 3: (A) initial FLAIR MR image (B) Demonstration of new T2 lesion 









Figure 4: (A) Demonstration of enlarging T2 lesion (ROI) on initial FLAIR 
image (B) Demonstration of enlarging T2 lesion (ROI) on final FLAIR image 
 
2.1.7 Total lesion volume (TLV) 




2.2 Coordinate based random effect size meta-analysis 
All CBRES and CBMAN analyses are performed using NeuRoi 
(https://www.nottingham.ac.uk/research/groups/clinicalneurology/neuroi.a
px), which is available to use freely. Details about the algorithms 
incorporated into CBRES and CBMAN are presented in 147,148. In both 
algorithms a clustering algorithm149 is used to determine where the 
coordinates reported by multiple independent studies are spatially 
concordant (clustered). Once clusters are formed, the reported Z scores are 
converted to standardised effect sizes by dividing by the square root of the 





effect sizes is performed in each cluster. In CBMAN, the test statistic is the 
correlation of standardised effect sizes performed pairwise between 
clusters. Where a study does not report a coordinate within a cluster, or 
where no effect sizes are reported by a study, the contribution to the cluster 
is estimated using the study censoring threshold. The significant results of 
the CBRES meta-analysis are clusters of reported coordinates where the 
estimated effect size is statistically different to zero after controlling the false 
cluster discovery rate (FCDR), a type 1 error control method based on the 
false discovery rate (FDR)150. The expected proportion of clusters 
incorrectly declared significant is controlled at 5% by default. Clusters 
indicate both spatial and effect size concordance across studies, which is 
an unlikely chance event suggesting that atrophy at the location of the 
clusters is a general feature of MS. 
Significant results reported by CBMAN are clusters where standardised 
reported statistical effects are correlated between clusters. This indicates a 
significant pattern of reported effect that is represented as a network of 
nodes (clusters) and edges (correlations). The FDR is used to control type 
1 error rate of the effect size correlations. The clusters analysed by CBMAN 
and CBRES are identical, since the same clustering algorithm is employed, 
but the results may differ due to the different hypotheses tested. 
A feature of both CBRES and CBMAN is that the results declared significant 
are reported as a functionof the FDR. Any that just miss the threshold for 
significance can therefore be explored. Analysis can also be performed on 
subgroups of studies. This estimates a subgroup-specific effect size in each 
of the clusters found significant during the full analysis (using all studies); 
this is useful since clusters may not be significant if the subgroup is small, 
yet the effect size might be of interest. Furthermore, the use of standardised 
effect sizes makes meta-regression possible by looking for significant 
correlation between a specified covariate and the standardised effect size 




2.3 Voxel Based Morphometry 
FSL’s standard VBM processing pipeline was adopted, and the processing 
steps have been briefly described below. The basic VBM protocol, defined 
in151 consists of five steps: 1. Template creation 2. Spatial normalisation 3. 
Segmentation 4. Smoothing 5. Statistical Analysis. 
Using the FSL 5.01 tools152 on Centos 7 operating system, brain extraction 
was performed on all individual 3D T1-weighted images using BET153. 
Following this, tissue-type segmentation was carried out using 
FASTv4.1154. FAST does not use prior information for determining the 
different tissue classes, instead it applies a hidden Markov random field 
model with the Expectation Maximization algorithm to associate each 
intensity value from the anatomical image with a specific mixture of GM, 
WM and CSF probabilities. The resulting GM probability images were 
normalized to ICBM152 standard space by using the standard FSL template 
and the affine registration tool FLIRT155,156, followed by nonlinear 
registration executed by FNIRT157. The resulting images were flipped and 
averaged to create a symmetric, study-specific template. In a second 
iteration, the native GM probability maps were non-linearly re-registered to 




Figure 1: Workflow of a VBM analysis. The analysis is based on 3D 
structural brain images. First, the T1-weighted 3D images undergo 
correction for inhomogeneities followed by classification into different tissue 
types. The gray matter segment (i.e., the tissue of interest) is spatially 
normalized to match a study-specific template. Subsequently, the 
normalized gray matter segment is smoothed with an isotropic Gaussian 
kernel. Finally, the smoothed normalized gray matter segments are entered 
into a statistical model for conduction of voxel-wise statistical tests and 






Imaging analysis for hookworm treatment in RRMS 
 
Abstract 
IMPORTANCE Studies suggest gut worms induce immune responses that 
can protect against multiple sclerosis (MS). To our knowledge, there are 
no controlled treatment trials with helminth in MS. 
 
PURPOSE To determine whether hookworm treatment has effects 
on MRI activity and T regulatory cells in relapsing MS. 
 
DESIGN, SETTING, AND PARTICIPANTS This 9-month double-blind, 
randomized, placebo-controlled trial was conducted on relapsing MS 
patients without disease-modifying treatment. 
 
INTERVENTIONS Patients were randomized (1:1) to receive either 25 
Necator americanus larvae transcutaneously or placebo. The MRI 
scans were performed monthly during months 3 to 9. 
 
MAIN OUTCOMES AND MEASURES The primary end point was the 
cumulative number of new/enlarging T2/new enhancing T1 lesions at 
month 9. 
 
RESULTS The median cumulative numbers of new/enlarging/enhancing 
lesions were not significantly different between the groups by preplanned 
61 
 
Mann-Whitney U tests, which lose power with tied data (high number of 
zero activity MRIs in the hookworm group. 
 
3.1 Worms as therapeutics 
MS has been considered as a Th1-Th17-mediated inflammatory auto-
immune response that is an organ-specific inflammatory autoimmune 
disorder158,159. 
Helminth parasites potently manipulate the regulatory T cells in the host. A 
numerical expansion in both natural and induced regulatory T-cells (T regs) 
is accompanied by qualitative changes to activation markers and increased 
suppressive function. These T regs suppress excessive inflammation 
caused by autoimmunity. 
Different groups have made an attempt to identify and utilize the protective 
effect of helminth-derived single components for the modulation of immune 
response in autoimmune diseases, in recent animal studies160.  
3.2 Helminths in MS clinical trials 
Recommendations for clinical trials of helminth therapy in autoimmunity 
have been published recently.161 Trichuris suis and Necator (N.) 
americanus are the helminth species employed in clinical trials of helminth 
therapy in MS. They are selected due to their safety profiles with regards to 
controlled infection.  
N. americanus is a gastrointestinal pathogen infecting over 500 million 
people. It is encountered only in humans making it a ‘family heritage’ and 
an evolutionary ‘old friend’ that has accompanied humans during historical 
migration162. N. americanus infection is generally benign following the 
establishment of adult worms in the gut.162–164. There is a possibility of 
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gastrointestinal symptoms due to acute infection but dose-ranging studies 
have demonstrated that light infection is asymptomatic165,166.  
A successful parasite-host relationship thrives on commensalism, where 
the parasite causes little-to-no overt damage to its host, and approaches 
mutualism, that consists of derivation of some benefits for the host, from the 
parasite164,167,168. This helminth satisfies this profile due to its possible 
benefits in treating MS or other chronic inflammatory diseases168.  
There has been evaluation of the safety and therapeutic validity for various 
inflammatory diseases where low dose of N. americanus infection has been 
demonstrated to be safe as well as tolerable163,167,169,170. 
Clinical trials of helminth therapy in MS have recently been reviewed171. 
HINT (Helminth-induced immunomodulation therapy) study- This study 
was conducted by Fleming and colleagues at the University of Wisconsin, 
USA. In the first part of this trial (HINT 1), Trichuris suis ova (TSO) was 
administered orally every 2 weeks for 3 months to treat five RRMS subjects.  
MRI of brain was performed at baseline, monthly for 3 months and at 2 
months after the end of treatment with TSO. 
Results: The mean number of new active brain lesions was 6.6 at baseline, 
5.8 at 2 months post-treatment and 2.0 after 3 months of treatment.  
It was noted by the authors that the encouraging MRI results require prudent 
interpretation due to the small number of subjects and the short observation 
period172. 
The study reported no adverse clinical effects in the subjects. 
HINT (Helminth-induced immunomodulation therapy) 2 study- This was 
a follow-up exploratory clinical trial. It had a baseline versus treatment 
design and, involved 15 RRMS patients naïve to treatment172. The recruited 
patients underwent 5 months of pre-treatment observation followed by 10 
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months of treatment with Trichuris suis ova (administered orally every 2 
weeks). 
 The primary outcome measures involved safety and tolerability of Trichuris 
suis ova and changes in the number of contrast-enhancing lesions as 
observed during monthly brain MRI scans with gadolinium contrast44. No 
significant safety and tolerability issues were observed. The study reported 
no serious side effects or adverse events associated with the treatment. 
The cohort showed 35% reduction in active lesions when observation MRIs 
were compared to treatment MRIs. There was an association observed 
between TSO and elevation in Treg cells as well as modification in Th2 
immune response, according to the immunological tests. The modest 
reduction observed in contrast-enhancing lesions during the treatment 
course suggested the requirement of further investigation of TSO for the 
assessment of its effectiveness in RRMS173.  
Pilot study for SPMS- A study of helminth therapy in SPMS was conducted 
by Benzel and colleagues at the Charite University, Berlin, Germany174. The 
study recruited four SPMS subjects and, consisted of 6 months of treatment 
with 2,500 TSO that were administered orally every 2 weeks. The patients 
were observed to be clinically stable during the study, and treatment was 
well tolerated174.  
Rosche and colleagues175 have started work on a phase II study with an 
aim to recruit 50 RRMS patients who will be administered either TSO or 
placebo for a period of 12 months (Trichuris suis ova in relapsing-remitting 
multiple sclerosis (TRIOMS) and clinically isolated syndrome). 
Comparing HINT2 and TRIOMS, the latter included fifty RRMS or CIS 
patients with clinical activity as well as not undergoing any standard 
therapies. The patients were randomized to obtain Trichuris suis ova every 
2 weeks or placebo. The authors aimed to assess the safety, tolerability and 
influence on disease activity, along with the in vivo mechanisms of action of 
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the helminth ova by means of laboratory, neurological, immunological 
exams and MRI over a period of 12 months followed by a follow-up of 6 
months. However, the results for this study have not been posted yet. 
TRIMS A was an open label, MRI assessor-blinded study, involving 10 
RRMS patients. The patients were treated with TSO orally for a period of 3 
months. Six out of ten patients were concomitantly administered β-
interferon. MRI was done every 3 weeks. It was concluded by the 
investigators that TSO was well tolerated and safe but none of the clinical, 
immunological or MRI signals observed indicated a benefit176. 
The trial was designed to test safety instead of drug effectiveness. In 
addition, the association of disease-modifying therapies in more than half 
of the recruited patients, the brief follow-up and the small patient sample do 
not allow any conclusions to be drawn from this study with regards to 
effectiveness of helminth therapy.  
WIRMS142 was the first phase II randomised double-blinded placebo-
controlled of treatment with hookworms in relapsing MS that had been held 
at the University of Nottingham (Worms for Immune Regulation of MS 
(WIRMS))177. The trial recruited 72 RRMS patients for treatment with 
dermally administered hookworm (Necator americanus) larvae or placebo. 
The primary endpoint consisted of cumulative number of new or enlarging 
contrast-enhancing lesions at 9 months following intervention. In addition, 
several immunological parameters reflecting expression and activity of 
Tregs as well as Th2 shift were secondary and exploratory outcome 
measures. MRI scans were conducted monthly. Safety analysis in between 
the administration and deworming as per January 2015 advocated good 
tolerability and safety of this treatment.  
Pilot MS studies with helminths have demonstrated a very decent safety 
profile, along with encouraging effects on clinical, radiological and 
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immunological outcomes. Phase II study results are essential for confirming 
the favorable indications hinted by epidemiological, preclinical and 
observational along with pilot therapeutic studies concerning effectiveness 
of helminth therapies in MS171. 
WIRMS clinical trial: MRI analysis 
3.3 Study introduction 
The purpose of this study was to determine whether infection, that is 
controlled with a clinically safe number of hookworm larvae, demonstrated 
protection towards reducing MRI activity in relapsing MS and lead to the 
induction of immunoregulatory mechanisms that suppress the overactive 
immune system.  
The worms for immune regulation in MS (WIRMS) study142 proposed to be 
the first controlled parasite exposure study in 36 patients with relapsing 
remitting MS (RRMS) with 25 hookworm larvae versus 36 patients with 
placebo (water). Sample size calculation for this study was based on 
Tubridy et al.178 for frequent gadolinium MRI (primary end point); that itself 
reported MRI disease activity in 80% of the study population. Assuming new 
lesion distribution similar to that study, using the Mann-Whitney U test to 
compare placebo and HW groups, 36 patients per arm (1:1 randomization) 
are needed to show 70% reduction (relative risk 0.3) between month 3 and 
month 9 with approximately 95% power (2-tailed significance of 5%).178  
Patients were observed clinically for relapses and disability scores, 
immunologically and radiologically for monthly MRI scans over a period of 
1 year. The primary outcome of this study considered the cumulative 
number of new and active T2 lesions. The induction of Tregs were 
considered as the immunological secondary outcome measure. Relapse 
rate was the secondary clinical outcome measure.  
66 
 
The study has potentially examined therapeutic immunomodulation 







Figure 6: MRI timeline for the clinical trial; long arrows represent visits 
at which MRI was conducted; worms were administered at month 
3/visit 7; M stands for month; V stands for visit. 
3.3.1 Primary outcome of the clinical trial: Newly active lesions 
The primary outcome of the WIRMS trial was MRI detectible disease activity 
between visits 7 and 13. This is a sum of new lesions, enlarging lesions, 
and newly enhancing lesions. These are defined as  
• New lesions: Comparing visit 13 to visit 7, a new lesion should be 
on 13 but not 7. 
• Enlarging lesions: Comparing visit 13 to visit 7, an enlarging lesion 
should be bigger at V13 than it was at V7. 
• Newly enhancing old lesion: looking at all visits 8, 9, 10, 11, 12, 
and 13 a newly enhancing lesion is one that is enhancing and was 
visible in the previous visit but not enhancing. Lesions can newly 
enhance more than once. The newly active lesions are a sum of 
these three components. 



























The study found no quantitative differences in the T2 lesion load on MRI at 
the baseline (V7) scan between participants assigned to receive HW 
(hookworm) or placebo. According to the data, the number of newly 
enhancing T1 lesions was numerically higher in the HW arm as compared 
to placebo at V8. 
 
At visit 13, the cumulative number of new T2 lesions, newly enhancing 
lesions or enlarging lesions was calculated to be 141 in the HW group and 
117 in the placebo group. Sixteen of the HW-treated patients (53%) 
versus eight of the placebo-treated patients (26%) had no detectable MRI 
activity. 
 





























Figure 7: Bland Altman plot showing agreement of newly enhancing T1 
lesion counts between two observers. Dashed lines = upper and lower limits 






Figure 8: Bland Altman plot showing agreement of new and enlarging T2 
lesion counts between two observers. Dashed lines = upper and lower limits 
of agreement; Bold line = Bias. 
 
The plot for newly enhancing T1 lesions (Figure 7), the bias of -0.03 units 
means less than 1 lesion difference between the two observers on 
average. The narrow limits show unbiased limits of agreement.  
 
Regarding the difference plot for new and enlarging T2 lesions (Figure 8), 























or less than observer 1. The narrow limits show unbiased limits of 
agreement. Many outliers are very close or on the line of limit of 
agreement.  
 




Figure 9: Histogram demonstrating the number of T2-weighted lesions at 
V7 for all HW-treated patients. 
 
As demonstrated in Figure 9, 8 patients show 0-10 T2-weighted lesions at 
the first visit. None of the patients’ scans demonstrate more than 50 T2-
weighted lesions, at V7, with 1 patient having the highest lesion load (41-




























Figure 10: Histogram demonstrating the number of T2-weighted lesions at 
V7 for all placebo-treated patients. 
 
As demonstrated in Figure 10, 10 patients show 0-10 T2-weighted lesions 
at the first visit. None of the patients’ scans demonstrate more than 50 T2-
weighted lesions, at V7, with 1 patient having the highest lesion load (41-























































































Regarding Figure 11, most patients (10) have TLV) ranging from 5001-
10000 mm3 in the HW arm. None of the patients’ scans demonstrate TLV 
more than 60000mm3 with two patients’ scans having highest TLV. 
 
As shown by the histogram (Figure 12), most patients (11) have a total 
lesion volume (TLV) ranging from 5001-10000 mm3 at V7. None of the 
patients’ scans demonstrate TLV of more than 60000 mm3 with one 































Figure 13: Histogram demonstrating the number of contrast-enhancing 




Figure 14: Histogram demonstrating the number of contrast-enhancing 
lesions at V7 for placebo-treated patients. 
 
 
As demonstrated in Figure 13, 22 patients in the HW group show 0 
contrast-enhancing lesions. 1 patient shows 7-9 enhancing lesions at the 
first visit. None of the patients’ scans demonstrate more than 9 enhancing 
lesions with 1 patient having the highest lesion load in the cohort. 
 
As demonstrated in Figure 14, 19 patients in the placebo group show 0 
contrast-enhancing lesions. 2 patients show 5-6 enhancing lesions at the 
first visit. None of the patients’ scans demonstrate more than 6 enhancing 
































Figure 15: The chart shows the number of newly enhancing T1 lesions in 













































Figure 16: The chart shows the number of patients with newly enhancing 
T1 lesions at each visit. 
 
The number of newly enhancing T1 lesions was found to be higher in the 
HW arm at V8. (Figure 15) 
The graph shows the number of patients with newly enhancing T1 lesions 
that is found to be higher in the Placebo arm at V13. (Figure 16) 
 
The number of newly enhancing lesions and patients with newly enhancing 
lesions was found to be numerically higher in the HW arm vs placebo at 
month 4 (V8) but was observed to shift downward between months 4 and 9 
while there appears to be an upwards trend in the placebo arm  
 




















































Figure 17: Bar chart showing the summary of the components of the 
primary outcome measure (total number of newly enhancing T1, new T2 
and enlarging T2 lesions) in the two arms. 
 
As can be seen in the bar chart (Figure 17), the total number of newly 
enhancing T1 lesions was 36 in the placebo arm and 31 in the HW arm. 
The total lesion count of new T2 lesions was lesser in the HW arm (73) as 
compared to placebo (90). Lesion count for enlarging T2 lesions was 
observed to be numerically higher in the HW arm (29) as compared to the 
placebo arm (15). 
 
Regarding the clinical trial, in the 71 randomized participants, the 
estimated difference in median range (placebo–HW) was 0 to 2 (P = .19; 
Mann-Whitney U test results adjusted for ties) when means were imputed 
and 0 to 3 (P = .26; Mann-Whitney U test results adjusted for ties) when 
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MRI has been widely accepted as a more sensitive disease activity marker 
as compared to clinical assessment. This has been commonly observed in 
clinical practice where MS patients often have new MRI lesions without new 
clinical symptoms.  
The analysis of lesion activity on serial MRI has been accepted widely as a 
measure of treatment effects. Contrast-enhancing lesions indicate foci of 
active inflammation, while T2-weighted lesions persist and accumulate; 
hence, the presence of enhancing lesions gives indication of currently active 
disease, while the overall T2 lesion burden provides a marker for cumulative 
disease progression.  
Early in the disease, T2 disease burden and the accumulation predict future 
disease severity.179,180 Therefore, MRI scanning in patients with MS is 
utilized for the purpose of diagnosis, counseling patients regarding disease 
severity and prognosis, and deciding the requirement for disease-modifying 
drug therapy and as a tool to screen and test new therapies. The variability 
in lesion quantification as a clinical trial metric has been well studied and its 
importance emphasized in the literature 181.  
 
3.5.1 Reproducibility Analysis 
The observations for new and enlarging T2 lesions could not be made for 
5 patients due to the missing scans, the reason being either unavailability 
of V7 scans or dropouts. The observations for newly enhancing T1 lesions 
could not be included for 13 patients in the final analysis due to 3 dropouts 
and 10 patients with missing scans. 
 
Both the Bland-Altman plots demonstrate good agreement between the 2 




3.5.2 T2 lesion load at baseline 
Regarding the WIRMS study, number of T2 lesions were matched at 
baseline for the two arms. 
3.5.3 Alterations in T1 lesions  
Regarding the WIRMS trial, 51% of HW-treated patients demonstrated no 
new, enlarging or enhancing lesions during the study. This raises the 
possibility that the HW had an anti-inflammatory effect.182 The number of 
newly enhancing T1 lesions was found to be higher in the HW arm at V8.  
 
Regarding the chart showing the number of patients with newly enhancing 
T1 lesions, this was found to be higher in the Placebo arm. The reason for 
this is that it was the same HW-treated patients that had enhancements 
however, there were many enhancements. The placebo group, on the other 
hand, had fewer enhancements, but always different patients so, there were 
more patients with enhancements overall. 
 
Re-enhancing T1 lesions represent larger areas of inflammation according 
to the study conducted by Campbell and colleagues183. 
 
3.5.4 New disease activity 
The 2 arms in the WIRMS trial were matched for MRI activity at baseline. There 
was no new disease activity observed, during the trial, in 51% of patients treated 
with HW.182 
The number of newly-enhancing lesions and patients with newly-enhancing 
lesions was higher in the HW arm versus placebo at month 4 but showed a dip 
between visits 8 and 13 whereas it shifted upwards in the placebo arm. 
Accepting the small number of lesions, a trend towards reducing MRI activity with 
treatment in the HW arm can be hypothesized.  
3.5.5 Total Lesion Volume 
In a study conducted by Lewanska and colleagues184, the mean total T2 
lesion volume at baseline for the placebo group was calculated to be 
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between 10,000 and 15,000 mm3 for RRMS patients administered with 
either two different doses of intravenous immunoglobulin or placebo. This 
signifies that the population recruited for this study is representative of 
RRMS. 
 
3.5.6 WIRMS clinical trial 
In this 36-week phase 2 trial of HW in relapsing MS, no difference was 
observed between the cumulative number of active MRI lesions in the 2 
groups (primary outcome). However, the higher proportion of scans with 
no new disease activity in HW group i.e. 51% of patients treated with HW 
showing no new, enlarging or enhancing lesions, indicates a beneficial 
effect. The 2 arms in the WIRMS trial were matched for clinical and MRI 
activity at baseline.178  
Sample size calculation for the clinical trial was based on Tubridy et al.178 
for frequent gadolinium MRI (primary end point). Assuming the new lesion 
distribution to be similar to that study, utilizing the Mann-Whitney U test for 
the comparison between placebo and HW groups, there was a 
requirement of 36 patients per arm (1:1 randomization) for demonstrating 
70% reduction between month 3 and month 9 with approximately 95% 
power.178  
The primary outcome for the WIRMS clinical trial was the number of new, 
enlarging or newly enhancing lesions by month 9. The results showed that 
eighteen of the patients treated with HW (51%) and 10 of the patients 
treated with placebo (28%) had no detectable MRI activity. The per-
protocol analysis involving 54 patients with complete data sets, 
demonstrated 16 patients in the HW group vs 8 patients in the placebo 
group with no MRI changes.  
There was a higher number of tied zero-activity counts than expected in 
the HW arm, meaning a higher number of MRI scans with no disease 
activity, considering the sample used to power the study, in which 6 out of 
31 patients demonstrated no new activity over the trial period.178 This 
resulted in the planned Mann-Whitney U test being inappropriate because 
it loses power in the presence of ties.185 The high rate of no detectable 
MRI activity in HW arm, although resulted in reduced study power, 




Localised Grey Matter Atrophy in Multiple 
Sclerosis and Clinically Isolated Syndrome—A 
Coordinate-Based Meta-Analysis, Meta 
Analysis of Networks, and Meta-Regression of 
Voxel-Based Morphometry Studies 
 
Abstract 
Background: Atrophy of grey matter (GM) is observed in the earliest 
stages of multiple sclerosis (MS) and is associated with cognitive decline 
and physical disability. Localised GM atrophy in MS can be explored and 
better understood using magnetic resonance imaging and voxel-based 
morphometry (VBM). However, results are difficult to interpret due to 
methodological differences between studies. Methods: Coordinate based 
analysis is a way to find the reliably observable results across multiple 
independent VBM studies. This work uses coordinate based meta-
analysis, meta-analysis of networks, and meta-regression to summarise 
the evidence from voxel based morphometry of regional grey matter (GM) 
changes in patients with multiple sclerosis (MS) and clinically isolated 
syndrome (CIS), and if these measured changes are relatable to clinical 
features. Results:  Thirty-four published articles reporting forty-four 
independent experiments using VBM for the assessment of GM atrophy 
between MS or CIS patients and healthy controls were identified. Analysis 
identified eight clusters of consistent cross-study reporting of localised GM 
atrophy involving both cortical and subcortical regions. Meta-network 
analysis identified a network-like pattern indicating that GM loss occurs 
with some symmetry between hemispheres. Meta-regression analysis 
indicates a relationship between disease duration or age and the 
magnitude of reported statistical effect in some deep GM structures. 
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Conclusions: These results suggest consistency in MRI detectible regional 
GM loss across multiple MS studies, and the estimated effect sizes and 




Areas of inflammation, axonal loss, demyelination and gliosis, occurring 
throughout the brain and spinal cord, are the distinctive features of 
Multiple Sclerosis (MS)186. Although MS has been considered a condition 
affecting the white matter (WM) and the hyperintense lesions on T2 
weighted images are for MS diagnostics, there is a limited association 
between lesion accrual and disability. Atrophy measures appear to be a 
more specific marker of MS pathology than lesion volumes 187, as 
demonstrated by the association of atrophy in the brain and spinal cord 
with increasing disability 188. In addition, progressive ventricular 
enlargement, another indicator of atrophy, has been shown to predate 
clinically definite MS in patients with clinically isolated syndrome (CIS) 189.  
Atrophy of GM is already observed in the initial disease stages 122 and an 
association has been observed with cognitive decline and physical 
disability 190.  The underlying mechanism for GM atrophy is unknown, but 
several hypotheses have been postulated including primary GM damage 
involving neuronal loss, demyelination, reduced synapses, decreased 
oligodendrocytes and axonal transection 191. An association has been 
demonstrated between GM loss and WM lesion load even in patients with 
short disease duration 136,192–194.  
The importance of GM loss in MS necessitates careful analysis using 
advanced imaging methods such as voxel-based morphometry (VBM). 
Multiple VBM analyses of MS or CIS patients compared to healthy control 
groups have been published and significant changes interpreted as 
82 
 
atrophy. VBM has been shown to be robust against various processing 
steps with false positives randomly distributed about the brain 195 
However, studies often involve small sample sizes, and with lack of power 
comes increased chance that any observed effect is a false positive 196. 
Moreover, uncorrected p-values are commonly employed, inflating the 
false positive rates 197. A further complexity of VBM was highlighted by a 
study 198 comparing detectable GM changes by different software 
packages- FSL 199, FreeSurfer 200,201, SPM (Statistical Parametric Mapping 
Functional Imaging Laboratory, University College London, London, UK). 
The study examined agreement between these packages by using an MS 
cohort with a common disease type with matched controls and highlighted 
pronounced differences.  
Given the problems with single studies, there is potential for meta-
analyses to reveal which of the observed effects are most likely to indicate 
MS specific GM changes. Results can add to the understanding of GM 
pathology in MS, and provide specific hypotheses for testing. In the 
absence of the original images, a coordinate based meta-analysis (CBMA) 
is possible using only the summary reports tabulated in the large majority 
of VBM publications.  Results indicate effects most reliably detectable by 
VBM.  
The primary aim of this meta-analysis was to determine the locations of 
consistent regional GM changes in MS and CIS patients by means of a 
coordinate based random effect size (CBRES) 147 meta-analysis and 
coordinate based meta-analysis of networks (CBMAN) 148.  Each of these 
algorithms cluster the reported coordinates where there is spatial 
concordance. CBRES performs conventional random effect meta-analysis, 
of the reported Z scores standardised by study sample size, in each 
cluster. CBMAN looks for network-like patterns of GM loss by considering 
significant correlations of standardised statistical effects between pairwise 
clusters. Secondary analyses involving subgroup analysis and meta-
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regression are also performed using CBRES. The coordinate data used in 
this analysis is made available on the Nottingham Research Data 
Management Repository [dataset](DOI: 10.17639/nott.7049) for validation 
purposes 202.  
4.2 Materials and Methods 
4.2.1 Search strategies 
A literature search was conducted using PubMed - with the following 
search term combinations- ("multiple sclerosis"[All Fields] OR "ms"[All 
Fields] OR CIS[All Fields] OR "clinically isolated syndrome"[All Fields]) AND 
("voxel based morphometry"[All Fields] OR VBM[All Fields]) AND 
("atrophy"[MeSH Terms] OR "atrophy"[All Fields]) AND ("grey matter"[All 
Fields] OR "gray matter"[All Fields] OR GM[All Fields]), Web of science, 
using the following search terms-TS=("multiple sclerosis" OR MS OR CIS 
OR "clinically isolated syndrome") AND TS=("voxel based morphometry" 
OR VBM) AND TS=(atrophy)  AND TS=("grey matter" OR "gray matter" OR 
GM) and Science direct, using the following search terms- TITLE-ABSTR-
KEY("multiple sclerosis" OR MS OR "clinically isolated syndrome" OR CIS) 
and TITLE-ABSTR-KEY("voxel based morphometry" OR VBM) and TITLE-
ABSTR-KEY("grey matter" OR "gray matter" OR GM) and TITLE-ABSTR-
KEY(atrophy).  
Study selection 
Inclusion criteria are (a) involved participants with MS or CIS (b) 
compared patients to healthy controls (c) performed whole brain VBM for 
assessing GM atrophy (d) reported coordinates for GM volume changes in 
either Talairach 203 or Montreal Neurological Institute (MNI) reference 
space. Exclusions were made due to unreported coordinates or unavailable 
full text. Two independent researchers assessed these criteria of the 
individual studies and the MNI or Talairach coordinates.  
Study properties 
Information extracted for analysis: the censoring threshold i.e. the 
smallest Z value the study considered as significant, the reported 
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coordinates, and either the Z score, estimated degrees of freedom and t 
statistic,  or uncorrected p-value; t-statistics and uncorrected p-values are 
converted automatically to Z scores.  
Coordinate based Meta-analysis 
All CBRES and CBMAN analyses are performed using NeuRoi 
(https://www.nottingham.ac.uk/research/groups/clinicalneurology/neuroi.as
px), which is available to use freely. 
Details about the algorithms incorporated into CBRES and CBMAN are 
presented in 147,148 . In both algorithms a clustering algorithm 204 is used to 
determine where the coordinates reported by multiple independent studies 
are spatially concordant (clustered). Once clusters are formed the reported 
Z scores are converted to standardised effect sizes by dividing by the 
square root of the number of subjects. In CBRES, a random effect meta-
analysis of these effect sizes is performed in each cluster. In CBMAN, the 
test statistic is the correlation of standardised effect sizes performed 
pairwise between clusters. Where a study does not report a coordinate 
within a cluster, or where no effect sizes are reported by a study, the 
contribution to the cluster is estimated using the study censoring threshold.  
The significant results of the CBRES meta-analysis are clusters of 
reported coordinates where the estimated effect size is statistically different 
to zero after controlling the false cluster discovery rate (FCDR); a type 1 
error control method based on false discovery rate FDR 150. The expected 
proportion of clusters incorrectly declared significant  is controlled at 5% by 
default. Clusters indicate both spatial and effect size concordance across 
studies, which is an unlikely chance event suggesting that atrophy at the 
location of the clusters is a general feature of MS.  
Significant results reported by CBMAN are clusters where standardised 
reported statistical effects are correlated between clusters. This indicates a 
significant pattern of reported effect that is represented as a network of 
nodes (clusters) and edges (correlations). FDR is used to control type 1 
error rate of the effect size correlations. The clusters analysed by CBMAN 
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and CBRES are identical, since the same clustering algorithm is employed, 
but the results may differ due to the different hypotheses tested. A feature 
of both CBRES and CBMAN is that the results declared significant are 
reported as a function of the FDR. Any that just miss the threshold for 
significance can therefore be explored. 
Analysis can also be performed on subgroups of studies. This estimates 
a subgroup specific effect size in each of the clusters found significant 
during the full analysis (using all studies); this is useful since clusters may 
not be significant if the subgroup is small, yet the effect size might be of 
interest. Furthermore, the use of standardised effect sizes makes meta-
regression possible by looking for significant correlation between a 
specified covariate and the standardised effect size in each cluster.  
Experimental Procedure 
Multiple experiments reported on the same subjects were pooled into 
single independent experiments to prevent correlated results inducing 
apparent concordance that is not due to a generalizable MS process 205.  
All planned analyses were performed controlling the FDR at 0.05. For 
each the next most significant clusters were explored, and reported, to 
make sure that none had just been missed at this threshold.  
Main analysis 
The main meta-analysis was performed using both CBRES and 
CBMAN and involved all studies meeting the inclusion criteria.  
Subanalyses 
Subanalyses for CIS, benign MS (BMS), Relapsing Remitting MS 
(RRMS), Primary Progressive MS (PPMS) and Secondary Progressive MS 
(SPMS) studies were performed; subtypes as defined in the reporting 
studies. This analysis estimates effects of the respective subgroup within 
significant clusters discovered using all studies. 
Meta-regression 
Regression analyses were performed for covariates that might 
influence the grey matter volume: mean age (years), MS disease duration 
86 
 
(years; excluding CIS studies with no MS disease duration), MSFC, and 
EDSS (all studies and including RRMS studies only). 
4.3 Results 
4.3.1 Included studies and sample characteristics 
The literature search yielded 237 potential studies of which 34 met the 
inclusion criteria (Figure 1). The 34 included research papers reported 45 
whole brain VBM experiments comparing MS subtypes and controls (See 
supplementary materials for study details). 
 
Figure 1. This is a figure with the PRISMA flowchart 206 showing the 
inclusion and reasons for exclusion of studies in the meta-analysis.  
Studies included in the analysis were conducted between 2006 and 2018 
and involved a total of 1561 patients and 1182 controls. The studies by 
MS subtype were 4 CIS, 24 RRMS, 7 PPMS, 3 BMS, and  2 SPMS; 4 
studies were not specific to any single MS subtype. Mean patients age 
was 40.49 years (SD =.64). The number of controls varied in size from 9 
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to 90 and patients varied from 9 to 249. The mean (standard deviation 
(SD)) EDSS was 2.7 (1.5). The mean disease duration was 9.26 (6.51) 
years. Across the studies the duration of disease, excluding the CIS 
studies, was 1.66 to 30.50 years. 
4.3.2 Primary Meta Analysis 
The analysis found 8 significant clusters involving basal ganglia and 
cortical regions; effect sizes are given in Table 1 and the complete list of 
Talairach regions, automatically detected (26), covered by each cluster 
given in online materials [dataset](DOI: 10.17639/nott.7049) (21).  
Significant clusters and a depiction of the covariance of standardised 
effect sizes between clusters are shown in Figure 2. Forest plots for the 
most significant clusters according to CBRES are shown in Figure 3. In 
figure 4 a scatter plot of standardised effect sizes reported in the left and 
right thalamic clusters shows clear correlation detected by CBMAN. The 
first non-significant cluster according to CBRES was at a FCDR of 0.18. 
The first non-significant edges discovered by CBMAN were at FDR 0.057, 
where a further 9 significant edges and two extra clusters (right Caudate 
peaking at Talairach coordinates {12,4,20}mm  and another covering 
mostly the left/right cingulate gyrus peaking at {-4, -18, 44}mm) are found. 
Table 1: shows significant clusters detected by CBRES and CBMAN 
algorithms for the main meta-analysis and estimated effects from the 
subanalyses. The column ‘main analysis’ shows effect size, standard 
deviation and false cluster discovery rate for each significant cluster 
estimated using CBRES. The subsequent columns show the estimated 
effect size for the subanalyses; - signifies no contribution of the subgroup 
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Figure 2: Top: Significant clusters of GM atrophy detected using CBRES 
and CBMAN algorithm. Cluster (7) is detected only by CBMAN. Bottom: 
The network edges found to connect the clusters significantly by CBMAN; 
line thickness indicates correlation strength of the standardised effect 
sizes between connected clusters.  
 
Figure 3: Forest Plots for the two most significant clusters (left and right 
Thalamus) of GM atrophy reported by the 45 VBM experiments. Markers 
with solid circle indicate the effect size reported by the study in the 
respective cluster. The solid horizontal lines span ± 1.96 times the within 
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study standard deviation of the effect size. Censored values are depicted 
by open circle markers and the intervals by dashed lines (o). 
 
Figure 4. Relationship between standardised effect sizes reported in the 
left and right thalamic clusters. Markers that fall on the axes are censored. 
4.3.3 Subanalyses 
Results from the subanalysis are given in table 1, which shows estimated 
effects sizes considering only the respective subgroup within each of the 
clusters from the primary meta-analysis. It is apparent that the estimated 
effects are lowest in magnitude in CIS and PPMS groups and highest  in 





A single cluster was found with age as a significant covariate; table 2. The 
first non-significant cluster was at FCDR 0.18. 
Table 2: The table shows significant clusters for the Age and Disease 
Duration meta-regression. The location indicates the most commonly 
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4.3.4.2 MS Disease Duration 
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This analysis included 39 of the independent experiments reported MS 
disease duration due to exclusion of CIS studies where MS disease 
duration is zero. Three clusters were found with disease duration as a 
significant covariate; table 2. The first non-significant cluster was found to 
be at FCDR 0.1. 
 
4.3.4.3 MSFC 




No significant clusters with EDSS a covariate. The first non-significant 
cluster was found at FCDR 0.1. 
4.4 Discussion 
The results of 34 voxel-based morphometry studies of MS and CIS are 
summarised using CBMA, showing that GM atrophy in MS not only occurs 
in some regions more than in others and that regions of predilection are 
not independent.  Eight regions were identified using two algorithms 
testing different null hypotheses. Results indicate a consistent pattern, 
rather than independent clusters, of reported effects both spatially and in 
terms of effect size. 
The pattern of localised GM atrophy involves both cortical and subcortical 
regions. Considering the correlation of reported statistical effect size 
suggests that these regions do not develop independently, but rather 
together and with some hemispheric symmetry as shown in figure 2. Meta-
regression analysis suggests that the standardised effect magnitude 
increases with disease duration by several % per year of disease on 
average. This is also reflected in the mean statistical effect size estimates 
94 
 
within the disease type subgroups, where the estimates for the CIS group 
tend to be lower than the RRMS group, which are in turn lower than the 
SPMS group. The PPMS subgroup reported intriguingly low statistical 
effect sizes while the BMS group almost as large as the SPMS group in 
some clusters, which might reflect that BMS is indistinct from MS with long 
enough follow up. These estimates should be considered with caution 
because of the small subgroup sizes, however they could be prospectively 
tested. 
GM tissue damage is an important pathological process in MS that 
underlies neurological disability 123. It has been suggested that distribution 
of cortical GM atrophy is related to the effects of WM lesions on cortical 
regions that are network hubs, with trans-synaptic degeneration then 
extending from these hubs 140, or that the preferential accumulation of WM 
lesions in some regions would induce tract-mediated effects through 
secondary retro- or anterograde degeneration. The relationship between 
GM atrophy and WM abnormalities is weaker in people with PPMS or 
SPMS 207. The loss of volume is the result of many dynamic processes, 
with a balance between destructive and reparative mechanisms with 
interaction among neurons, oligodendrocytes, axons, microglia, 
astrocytes, inflammatory cells, endothelial cells and water distribution 208.  
In the thalamic clusters the standardised effect sizes were found to 
correlate negatively with disease duration. Both imaging and pathology 
studies have demonstrated the involvement of thalamus in early RRMS 
209, CIS 210 and pediatric MS 211. Cifelli and colleagues 212 conducted a 
study of normalised thalamic volume measurements in SPMS patients. 
Volumes of manually outlined thalami were normalised by intracranial 
volumes and showed a mean decrease of 17%. Thalamic volume loss 
may be due in part to disconnection created by WM lesions 213,214.  
Atrophy of the left and right putamen MS has also been detected. The 
putamen is a part of the dorsal striatum and the basal ganglia and, plays a 
95 
 
role in the regulation of movement, coordination, motor function and 
cognition 215–217. It is also involved in modulation of sensory and motor 
aspects of pain. 218 Thus, a pathology like, neurodegeneration, might be 
expected to cause a broad spectrum of clinical manifestation from motor 
dysfunction to psychiatric disorder. 219,220. Previous studies have 
demonstrated progressive atrophy of the putamen in both RRMS and 
SPMS 125. Kramer and colleagues 221 recently reported a significant 
relationship between putamen volume and disease duration in MS, which 
was also indicated by the present study. 
Pre- and postcentral gyrus (bilateral) is consistently reported. The clusters 
have density peaks reported in the right precentral and the left postcentral 
gyrus, but the coordinates forming the clusters cover both pre- and 
postcentral gyrus on each side.  Li et al 222 used diffusion tensor imaging 
(DTI) and demonstrated neuroconnectivity changes in the left postcentral 
gyrus, and reduced communicability correlating with the 25-foot walk test 
results.  
 
Clusters covering the left/right superior temporal gyrus and insula ware 
also detected. The superior temporal gyrus is associated with auditory and 
speech comprehension 223,224 and perception of emotions in facial stimuli 
225,226. In addition, it is an essential structure in the pathway containing 
prefrontal cortex and amygdala that are responsible for social cognition 
processes 225,227. The study conducted by Achiron and colleagues 228 
suggested correlation between reduced cortical thickness in superior 
temporal gyrus and global cognitive score, attention, information 
processing speed and motor skills. The insula is primarily a visceral-
somatic region 229. Studies have shown relation between functional 
connections of the basal ganglia and insula and fatigue severity in case of 
MS patients 230–232.  
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A similar coordinate based meta-analysis in MS was performed by Chiang 
et al at the same time as the present study 233. That study used the 
popular ALE algorithm and produced similar results. The study also used 
functional meta-analytic connectivity modelling (fMACM) 234 to explore 
functional coactivation of clusters as a network, estimated using non MS 
studies. By contrast the present study investigates the network like 
properties of GM atrophy and uses the included MS specific studies.  
There are limitations to CBMA are that bias and methodological issues in 
the primary studies might be reflected in the results. Therefore, CBMA 
results should be considered hypothesis generating and used to inform 
robust prospective studies. To this end the presented results provide a-
priori regions of interest for testing as well as statistical effect size 
estimation for sample size calculations. 
4.5 Conclusions 
This CBMA of VBM studies of MS and CIS has identified a pattern of 
related cortical and subcortical GM atrophy. Relationships are indicated by 
the covariance of reported statistical effects. Disease duration was found 
to be a significant covariate of the standardized reported effect sizes in the 
thalamic clusters and a cluster covering the left claustrum/putamen/insula. 
The estimated statistical effect sizes may be important for powering 
prospective studies of GM atrophy in MS to test specific hypotheses.  
 
Appendix A 
Table A1: The table shows demographics for the included studies. 







STUDY CONTROLS PATIENTS 
 
n MEAN AGE SD/RANGE FEMALES SUBTYPE N MEAN AGE SD/RANGE FEMALES 
AUDOIN 2006  10 37 31-52 4 EARLY RRMS 21 36 27-55 16 
AUDOIN 2010  37 28 8  -  CIS 62 29 20-46  -  
BALTRUSCHAT 
2015  15 30.47 5.91 7 RRMS 17 32.82 6.41 11 
BISECCO 2017  52 37.3 13.1 33 RRMS 125 36.8 10.7 82 
BODINI 2009  23 35.1 7.9 12 EARLY PPMS 36 44.8 11.13 15 
BONAVITA 2011  18 39 10 10 RRMS 36 CI- 40.9 8.7 11 
 
 -   -   -   -  
  
CP- 40.5 6.9 10 
CECCARELLI 2008  21 40.9 24-62 14 CIS 28 30.7 21-43 15 
CECCARELLI 
2007BMS  20 36.8 6.8 13 BMS 19 41.5 5.6 15 
CECCARELLI 
2007RRMS   -   -   -   -  RRMS 15 33.3 7.8 12 
CECCARELLI 2009  17 51.3 26-68 11 
 
18 49.6 38-73 10 
CERASA 2013  20 36.9 5.8 14 RRMSnc 14 38.6 8.5 11 
CERASA 2013A   -   -   -   -  RRMSc 12 38.9 8.7 10 
DEBERNARD 2014  25 35.2 10.3 17 EARLY RRMS 25 37.2 8.6 22 
ESHAGHI 2014  19 37.6 34.4, 41.9 9 PPMS 36 42.8 39.4, 46.6 12 
GALLO 2012  15 36.3 20-53 10 RRMS 30 35.9 19-51 20 
GOBBI 2014  90 39.7 13.7 51 MIXED_MS 123 41.7 10.3 71 
GOMEZ 2013F  18 31.06 5.67 8 RRMS_fatigue 32 37.72 5.9 21 
GOMEZ 2013NF  18  -   -   -  RRMS_nonfatigue 28 34.96 5.87 18 




KHALEELI 2007  23 35.1 23-56 12 EARLY PPMS 46 43.5 19-65 19 
LIN AIYU 2013  11 39.5 13.2 7 RRMS 11 38.5 12.2 7 
          
MESAROS 
2008BMS  21 45.7 25-66 11 BMS 60 46.2 35-63 37 
MESAROS 
2008SPMS  21 45.7 25-66  -  SPMS 35 46.5 30-63 25 
MORGEN 2006  19 31.7 7.5  -  RRMS 19 33.05 8.26  -  
MUHLAU 2013  49 36.4 13 33 CIS or RRMS 249 36.8 10.7 62 
MORGE low 
PASAT 19 31.7 7.5  -  RRMS 10 36.7 8.05  -  
PARISI 2014CMS  9 54.4 12.1 6 CMS 9 50.2 11 7 
PARISI 
2014CORTMS  9 
 
 -   -  CORT-MS 9 48.9 9.9 7 
PRINSTER 2006  34 43.2 13.2 15 RRMS 51 38.6 7.5 36 
PRAKASH 2010  15 45.8 1.8 15 RRMS 21 44.2 1.9 21 
RICCITELLI 2012  88 39.7 18-65 51 RRMS 78 40.2 20-63 55 
RICCITELLI 2011F  14 38.7 8.4 8 RRMS Fatigue 10 38 7.7 6 
RICCITELLI 
2011NF  14  -   -   -  RRMS nonfatigue 14 38.6 8.5 8 
SANCHIS-SEGURA 
2016M  35 25.54 5.35  -  RRMS male 22 38.68 8.72  -  
SANCHIS-SEGURA 
2016F  28 27.96 7.85  -  RRMS female 34 40.85 10.18  -  
SEPULCRE 2006  15 43.2 10.9 6 PPMS 31 43.7 9.87 13 
SPANO 2010  20 40.5 11.07 12 BMS 10 44.5 6.5 8 













NGE MSFC EDSS SD/RANGE 
PAS







AUDOIN 2006  2.15 1.2-3.8 -0.348 1 0-3  -   -   -   -   -   -  
AUDOIN 2010  0.33 0-0.5 
 
1 0-3.5 40 10 13 3 0.831 0.043 
BALTRUSCHAT 
2015  4.53 3.5  -  2.24 1.09 48.12 6.94 12 2.72 0.84 0.023 
BISECCO 2017  9.6 8.7  -  2 0-6  -   -  12.9 3.7  -   -  
BODINI 2009  3.3 0.9  -  4.5 1.5-7 47.65 11.24  -   -   -   -  
BONAVITA 2011  11.86 7.08  -  2.8 1.1  -   -  12.5 3.9 0.82 0.03 
 
10.91 4.67  -  2.6 1.7  -   -  12.3 3.6 0.83 0.03 
CECCARELLI 
2008  0 0  -  0 0-1  -   -   -   -   -   -  
CECCARELLI 
2007BMS  20 15-30  -  2 1.0-3.0  -   -   -   -   -   -  
 1 
TAVAZZI 2015  31 47.9 14.5 20 PPMS 18 46.9 8.1 6 
VAN DE PAVERT 
2015PP  30 37.8 11.8 18 PPMS 25 52.5 9.8 14 
VAN DE PAVERT 
2015RR  30  -   -   -  RRMS 30 42.5 9.6 20 
VAN DE PAVERT 
2015SP  30  -   -   -  SPMS 25 52.8 7.6 14 
ZHANG 2017  29 37.79 10.29 17 RRMS 39 38.26 9.05 23 
DOCHE 2017  16 37.1 10.2 12 RRMS 23 34.2 9.3 19 




2007RRMS  6 
2.0-
10.0  -  1.5 1.0-3.5  -   -   -   -   -   -  
CECCARELLI 
2009  10.7 
4.0-
21.0  -  5.5 3.0-7.0  -   -   -   -   -   -  
CERASA 2013  8.8 4.4  -  2 1.5-4.5  -   -  13 5.0-17.0  -   -  
CERASA 2013A  12.1 8.7  -  2.5 1.0-4.0  -   -  13 5.0-17.0  -   -  
DEBERNARD 
2014  2.4 1.5 
0.4 
(0.6) 1.5 0-4.5 0.16 0.99 13.5 2.7  -   -  
ESHAGHI 2014  3.3 2.9,3.6 
 -1.2 (-
0.7,-
1.6) 4 1.5,7  -   -   -   -   -   -  
GALLO 2012  9.2 3.0-22  -  2.1 1.0-5.5  -   -   -   -   -   -  
GOBBI 2014  12.6 1.0-44  -  2 0-7.0 36.6 1.0-59  -   -   -   -  
GOMEZ 2013F  7.44 5.15  -  3.2 1.68  -   -   -   -  -   -  
GOMEZ 2013NF  5.14 3.69  -  1.96 1.2  -  -   -  -  -  -  
HENRY 2008  0.3 0.25 
1.9(1.
7) 1.1 0.8 -2.1 2.3  -   -  
n GMV = 
940(52)  -  
KHALEELI 2007  3.3 2.0-5.0  -  4.5 1.5-7  -  -  -   -   -   - 






NGE MSFC EDSS SD/RANGE 
PAS








2008BMS  22.7 15-40  -  1.5 0-3.0  -  -   -   -   -  -  
MESAROS 
2008SPMS  16.2 7.0-27  -  6 4.0-7.0  -   -   -   -  -   -  
MORGEN 2006  1.66 1.43  -  1 0-3.5 31 22-56 
15 
(colleg
e level)  -  -  
MUHLAU 2013   -   -  




PASAT 2.02 1.78  - 2 0-3.5 27 22-31 
15 
(colleg
e level)  -  -  
PARISI 2014CMS  14  4-20  - 3 1.5-6  -  - 10.6 2.9 
765 
ml 31 ml 
PARISI 
2014CORTMS  8  2-31  -  4 1.0-6.0  -  - 8.4 3.2 
655 
ml 110 ml 
PRINSTER 2006  13.1 6.4  - 2.6 1.5-4.5  -  -   -  -  -  - 
PRAKASH 2010  7.3 0.1  - 2.2 0-6 43 2.3 15.6 0.4  -   -  
RICCITELLI 2012  10  1-28  -  1.5 1-4.5  -  -  -  -  -   - 
RICCITELLI 
2011F  8.2 6.2 
 
1.5 1.5-2.0  -  -  -  -  -  - 
RICCITELLI 
2011NF  10.6 6.6  - 1.5 0-1.5  -  -  -  -  -  -  
SANCHIS-
SEGURA 2016M  6.45 5.53 
 
2.5 0-6.5 35.23 20.01 5  1-6 0.83 0.33 
SANCHIS-
SEGURA 2016F  8.82 7.47 
 
2.38 0-6.5 33.35 23.04 4  1-6 0.83 0.27 




0.79) 4.5 3.5-7 
-
0.002  -3.73-1.24  -  -  -  - 
SPANO 2010  17.1 4.5 
not for 
all pts 1.75  1-3  -  -  -  -  -  -  
TAVAZZI 2015  12.4 7.73  - 6 3.0-8.0  -   -   -   -   -   -  
VAN DE PAVERT 
2015PP  12 7.4 
 -0.62 
(0.81) 6 0-6.5 -0.7 1.38  -   -   -   -  
VAN DE PAVERT 
2015RR  11.5 10.5 
 -0.41 
(0.76) 1.75 1.0-6.5 -0.69 1.32  -  -  -  - 
VAN DE PAVERT 
2015SP  24 8.2 
 -0.77 
(0.66) 6.5 4.5-8.5 -0.94 1.12  -  -  -  - 
ZHANG 2017  7.69 5.96  -  2.24 1.58 
CI n CP separate 
values 11.9 3.68  -   - 
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DOCHE 2017  4.5 4.6 
 -0.70 
(1.04) 1.5 1.2  - 
 
- -  -  -  - 
WEYGANDT 
2017  11.7 7.2  - 4 2.5-6.0  - 
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Voxel-based morphometry reveals brain 
GM volume alterations in hookworm-
treated MS patients  
Abstract 
Previous literature and the coordinate-based meta-analysis143 conducted 
has demonstrated a preferential loss of grey matter (GM) in the dorsal 
striatum, primary somatosensory cortex, insular cortex, auditory cortex and 
the relay station of the brain as identified cortically and subcortically in 
multiple sclerosis (MS) and clinically isolated syndrome (CIS) patients. The 
objective of this study was to assess GM atrophy in the whole brain and 
regions of interest (ROI) by the utilization of standard voxel-based 
morphometry (VBM) pipeline. 
5.1 Introduction 
MS has been described as a chronic demyelinating disease of the CNS, 
affecting WM. However, it has been demonstrated by pathological12,235 and 
MR imaging236–240 studies that it also involves cortical regions and deep GM. 
A reduction in brain and specifically GM volumes has been detected in 
MS,241 even in the early disease stages,242 but it is unknown whether some 
GM areas are more susceptible to volume loss as compared to others. 
Understanding of the potential differential susceptibility to GM loss may help 
illuminate the clinical presentation and improve our understanding of the 
clinico-radiological dissociation present in some MS patients.243 The 
measurement and evaluation of regional atrophy could also be useful in 
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monitoring disease progression, by identifying areas more sensitive to 
volume loss, and in the planning of clinical trials. 
It is legitimate to argue that an inflammatory misbalance is at the origin of 
MS. Research on pro-inflammatory mechanisms in MS has been largely 
performed; and, the potential mechanisms that actively participate in 
resolving inflammation involve T-regs.244 Regarding the WIRMS clinical 
trial142 that was a 9-month double-blind, randomized, placebo-controlled 
trial conducted to determine whether hookworm treatment effects 
MRI activity and T regulatory cells in relapsing MS (chapter 3); the 
proportion of CD4+foxp3+CD127neg cells, that may be more specific for 
true Treg cells, was found to be significantly increased by HW. 
Measurement of brain atrophy is also considerably influenced by the 
amount of tissue fluids245, which is increased by active inflammation and 
vasogenic edema in WM plaques, and decreased during treatment with 
agents with strong anti-inflammatory properties (pseudoatrophy 
effect)245,246. As per the results of the WIRMS study142, more than half of the 
HW-treated patients demonstrated no new disease activity during the trial 
compared to about 28% in the placebo arm, suggesting that the HW 
probably had an anti-inflammatory effect. Voxel based Morphometry (VBM) 
analysis is an accurate method for the assessment of tissue-specific brain 
atrophy, that allows the comparison of local GM between groups of subjects 
involving the segmentation of brain volumes into GM, WM and CSF, 
normalization to a standard space, and GM atrophy quantification on a 
voxel-by-voxel basis.151,247 The output comprises of a statistical parametric 
map (SPM) highlighting regions where there is a statistically significant 
difference in WM or GM among the groups.  
The purpose of this study was to evaluate the difference in GM density in 
the MS patients recruited in the WIRMS trial. Although, the duration of the 
clinical trial is not long enough to observe an effect, we hypothesize higher 
GM atrophy in placebo-treated patients in the whole brain and specifically 
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The purpose of this VBM study was to investigate: 
(i) Statistically significant differences in GM density of whole brain 
and a-priori defined ROIs, between groups (Placebo and HW) in 
the change from V7 (Figure 1; chapter 3) to V13(Figure 1; chapter 
3), using general linear model (GLM). 
(ii) GM density changes in ROIs between HW and Placebo groups, 




56 RRMS patients (28 HW, 28 Placebo) recruited in the WIRMS clinical trial, 
with complete data.  
5.3.2 Structural MRI 
3D axial T1-weighted fast spoiled gradient echo (1x1x1 mm isotropic, 256 
x 256 x 156 matrix). 
5.3.3 Data Analysis 
All the structural MRI post-processing (Figure 1) was performed by a single 
observer. Whole brain and regional volumetry measurements were 
performed on the 3D T1-weighted images, using a standard VBM approach. 
The 3D MR datasets of all placebo and HW-treated patients were 
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processed using the following main steps: (i) normalization of all images to 
the MNI template. This was done by first estimating the optimum 12-variable 
affine transformation to match images and then optimizing the normalization 
using 16 nonlinear iterations. (ii) the spatially normalized images were 
segmented into GM, WM and CSF in accordance with the tissue probability 
maps. A nonlinear deformation field is estimated that best overlays the 
tissue probability maps on the individual subjects’ image. The accuracy of 
the segmentation was assessed by examining axial slices of each subject’s 
GM, WM and CSF image in the individual’s space. The accuracy of warping 
was assessed by displaying axial slices from each subject with edges from 
the atlas image. (iii) The normalized GM images were modulated by the 
Jacobian determinants based on the voxel to compensate for the effect of 
spatial normalization, as it may result in volume changes due to affine 
transformation (global scaling) and non-linear warping (local volume 
change). (iv) The normalized and modulated GM images were smoothed 
using a 12 mm full-width half-maximum (FWHM) Gaussian kernel as done 
before248.  
Following the above steps, I used Randomise that is FSL's tool for 
nonparametric permutation inference on neuroimaging data. 
Randomization was performed in the whole brain as well as in ROIs using 
the following command: 
randomise -i GM_mod_merg_s2 -o GM_mod_merg_s2 -d design.mat -t 
design.con -m GM_mask -n 5000 -T -V 
where, 
 design.mat and design.con are text files containing the design matrix and 
list of contrasts respectively. 
-n 5000 option facilitates the command to generate ‘n’ permutations of the 
data when building up the null distribution to test against.  





This command runs randomise with the generation of tstat maps 
demonstrating the comparison between groups.  
Further, ROIs were extracted for cortical/subcortical regions from NeuRoi. 
The randomization was performed in the whole brain as well as in ROIs. 
The corrected p value image was thresholded at 0.05 by setting the min to 
0.95 and max to 1 in fslview. Further, the statistically significant clusters for 
the contrasts were highlighted in the whole brain and ROIs. 
(1) The GM segmentation was binarized in the whole brain and in ROIs 
at 0.5, using fslmaths. 
(2) The GM density values were extracted for each ROI, using 
fslmeants. 
5.3.4 Defining ROIs 
The defining of ROI was performed in NeuRoi by filtering the image of all 
clusters found, as a result of coordinate-based meta-analysis, to extract 
individual ROIs. This was done by setting the upper and lower threshold to 
the required cluster number. 
5.3.5 Statistical analysis 
An analysis of variance (ANOVA): 2-groups, 2-levels per subject (2-way 
Mixed Effect ANOVA) was used to compare GM volumetry measurements 
between the placebo and HW groups. The following a-priori contrasts were 
assessed: (1) Placebo vs HW, in the change from V7 to V13, (2) V7-V13. A 
family-wise error (FWE) correction at p < 0.05 for multiple comparisons at 





The patients did not demonstrate any area of significant GM loss in the 
whole brain as well as in the ROIs when comparing HW and Placebo-
treated patients, in the change from V7 to V13 (FWE correction for multiple 
comparisons, p < 0.05). Figure 23 shows the scatter plots for GM density 
values in the two arms for the eight ROIs. Figure 22 shows the ROIs 
constructed for the analysis. No statistically significant difference in GM 





















Figure 22: Demonstration of ROIs constructed for the analyses; A. Right 
Thalamus B. Right Insula C. Right Precentral Gyrus D. Right Putamen E. 















Figure 23: Scatter plots demonstrating GM density values for the change 
from V7 to V13 in Placebo and HW groups for respective ROIs. 
 
 
Table 4: Difference in GM density values between the two groups in each 
ROI with 95% confidence intervals. 
 
5.5 Discussion 
The key objective of this study was to define the change in GM density in 
the MS patients recruited as part of the WIRMS clinical trial, by means of 
VBM. In previous studies, it was hypothesized that regional GM atrophy 
occurs in MS  and, they have demonstrated reduction of GM volume in 
several cortical and subcortical regions in MS patients249–254. In MS patients 
recruited in the trial, no statistically significant regions of difference in GM 
atrophy were observed in Placebo or HW-treated groups. The same result 
was observed in each of the ROIs. This result was expected because MS 
patients were treated with hookworms only for a period of 9 months and, 
this intervention period would not be enough to observe any difference in 
GM atrophy between the two groups. All disease-modifying treatments 
reduce the rate of brain volume loss and/or GM atrophy in RRMS.255  
However, according to the hypothesis that HW have an anti-inflammatory 
effect, we would expect lesser GM atrophy in the HW arm and, some degree 
ROI Mean (Placebo) Mean (HW) Difference of means 95% CI
Left Putamen 0.353 0.334 0.019 (0.003, 0.034)
Right Putamen 0.517 0.486 0.031 (0.01, 0.045)
Left Superior Temporal gyrus 0.417 0.403 0.015 (-0.003, 0.033)
Left Postcentral gyrus 0.270 0.258 0.012 (0.001, 0.023)
Left Thalamus 0.236 0.231 0.005 (-0.006, 0.017)
Right Thalamus 0.415 0.413 0.002 (-0.021,0.021)
Right Insula 0.403 0.363 0.040 (0.014, 0.066)
Left Precentral gyrus 0.272 0.257 0.015 (-0.0005, 0.030)
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of detectable atrophy would be expected in a non-treated/placebo-treated 
patient during this time-period.  
 
The included subjects had hypointensities on T1-weighted MRI and, this 
factor might confound the GM segmentations. because of some of the T1 
lesions having the same intensity as GM. For the reduction of potential 
technical biases when performing VBM analysis, masking of T1 lesions from 
the GM maps could be done in order to avoid misclassification of MS lesion 
as GM. Registration of the included scans looked reasonable as observed 
in movie mode for GM_mod_merg. The reason that a smoothing of 2mm 
was chosen is that, based on visual assessment of the imaging data, it 
provided a reasonable middle ground between removing noise and 
maintaining the underlying anatomy. In addition, a threshold of 50% was 
applied to the masks in order to ensure the inclusion of GM pixels 
exclusively. 
Further, for calculating the sample sizes for the situation where a treatment 
preserves 20% of the GM density, the calculated sample size (80% power; 
1-sided test) for each ROI is shown in Table 5. 
ROI Standardized 
effect sizes/5 
Sample size (80% power; 
1-sided test) 
Right Thalamus 0.254 192 
Left Thalamus 0.252 195 
Let Putamen 0.192 336 
Left Superior temporal 
gyrus/Insula 
0.17 428 
Right Superior temporal 
gyrus/Insula 
0.168 439 
Right Postcentral gyrus 0.174 409 





Right Putamen 0.16 484 
 








General Discussion and Conclusions 
The predominant, although sometimes confronted, view specifies MS to 
be an autoimmune disease in which immunopathology in the CNS 
undertakes a central role256. Regarding a specific autoimmunity 
mechanism in MS, many authors have favoured a primary abnormality of 
immunoregulation. In MS, there is a numerical or functional deficit of Treg 
cells, and DMT increases Treg cell number as well as activity.257 Elevated 
inflammatory responses may reflect defective immunoregulation258. 
If microbial deprivation according to hygiene hypothesis, causes abnormal 
immunoregulation and if helminths have the ability to promote normal 
immunoregulation, the question that naturally would arise is whether 
controlled helminth infection might be therapeutic in MS and related 
conditions.44 
The WIRMS research project involved the analysis of new disease activity 
in the recruited RRMS patients. This was done by the observation of 
newly enhancing T1, new T2 and enlarging T2 lesions on MR images and 
was the primary outcome of the clinical trial. In addition, I looked at the 
contrast-enhancing T1 lesions, T2 lesion load and total lesion volume at 
baseline in the two arms. As controlled helminth infection has the potential 
to lead to immune regulation, the disease activity was analysed in 
recruited relapsing MS patients with the utilization of MRI (primary 
outcome of the clinical trial). The clinical study did not detect a difference 
between the cumulative number of active MRI lesions in the placebo and 
hookworm (HW) groups. However, the higher proportion of scans with no 
new disease activity in the HW group suggests a beneficial effect. 
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A subsequent clinical trial of HW infection should be conducted, as this 
phase 2 clinical trial showed a satisfactory safety profile. However, it 
would require higher power and will need to examine larger cohorts of 
patients. 
In the next chapter, a Coordinate-Based Meta-Analysis, Meta-Analysis of 
Networks, and Meta-Regression of Voxel-Based Morphometry studies143 
has been conducted to examine the influence that MS/CIS has on GM 
atrophy. This meta-analysis found eight significant clusters of GM atrophy 
in MS and CIS. These regions involved basal ganglia and the cortex. 
ClusterZ found 3 clusters with significant correlation for MS disease 
duration in the bilateral Thalamus and Left claustrum/putamen/insula and 
1 cluster with significant correlation for age in the Left Thalamus. 
GM tissue damage is an important pathological process in MS that 
underlies neurological disability.123 Previous literature shows differences in 
GM atrophy between MS subtypes involving a selective myriad of brain 
regions along with an increased extent of atrophy in common regions, 
such as the thalamus, in the progressive phase of the disease.259  
The CBMA results comprise of clusters of coordinates located where 
significant effect has been reported in similar anatomical locations, 
consistently by studies. This represents the concordance of brain 
structures reported along with indication of their relevance. Consistent 
reported coordinates are determined statistically relative to a null 
hypothesis that the coordinates in different studies are independent. The 
results provided by this study provide a quantitative summary of published 
evidence for a common pattern of regional GM atrophy in MS and CIS.  
When we compare the effect sizes for the primary metaanalysis and 
subanalyses in this study, the effect sizes get reduced in the subanalyses 
and the p values get larger. The effect sizes get decreased in the case 
when the number of studies, which contribute to a cluster, is small. So, as 
the number of subanalysis studies contributing to the defined clusters (by 
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all studies) become less, the effect sizes also get small. However, the p 
values are bigger for the subanalyses. This is because of the small 
number of subanalysis studies contributing to a cluster and, therefore, 
lower significance.  
The metaregression performed here with ClusterZ is a novel technique. 
The post hoc regression conducted performs a mean analysis to reveal 
the clusters with a significant mean. Further, it performs regression 
analysis only in the revealed clusters. For Metaregression of disease 
duration, I have removed the CIS studies (4) due to a disease duration of 
zero or few months.  
I tried to perform meta-regression tests on global GM volumes, brain 
parenchymal fraction, Multiple Sclerosis Functional Composite (MSFC), 
PASAT scores, years of education (Supplementary Table 1) and disease-
modifying therapy administered (Supplementary Table 2) but could not do 
that due to unavailability of the respective values in all included studies.  
Further, as an application of the regions of interest (ROI) found for GM 
atrophy, voxel-based morphometry (VBM) was conducted on 3D T1-
weighted MR scans acquired from relapsing MS patients recruited in the 
WIRMS clinical trial. This involved the analysis of GM density change in 
the two arms, during the period of intervention. 
Therefore, the outcome of the subsequent clinical study should involve 
GM volume change, along with WM disease activity. Although MS is 
classically considered a WM disease, the involvement of GM in the 
pathogenic process has been confirmed by pathology studies and MRI 
studies.190 The phase III trial of HW in relapsing MS will examine the effect 
of immunoregulation on WM lesions as well as regional GM atrophy, over 




The WIRMS clinical trial proved that treatment with hookworm was safe 
and well tolerated. The primary outcome did not reach significance, likely 
because of a low level of disease activity. An increase in T regs was 
observed with HW infection, suggesting an immunobiological effect of HW.  
 
The CBMA of VBM studies of MS and CIS has identified a pattern of 
related cortical and 
subcortical GM atrophy. Relationships are indicated by the covariance of 
reported statistical effects. Disease duration was found to be a significant 
covariate of the standardised reported effect sizes in the thalamic clusters 
and a cluster covering the left claustrum/putamen/insula.  
 
The VBM experiment did not find any statistically significant difference in 
GM density, between the placebo and hookworm arms, in the whole brain 






7.1 WIRMS clinical study 
 
A phase III clinical trial with higher power can be designed with a focus on 
WM as well as GM involvement in MS or CIS can be conducted. 
A subsequent clinical trial of hookworm (HW) infection should be 
conducted as this phase 2 clinical trial showed a satisfactory safety profile. 
However, it would require higher power and will need to examine larger 
cohorts of patients. With probability in group 1 (HW) = 0.43 and in group 2 
(Placebo) = 0.69; calculated by the number of patients with active MRI 
divided by the total number of patients in the group; the total sample size 
required is 105 i.e., 52 per group. Also, it would be a good option to power 
the study by the number of patients with no new disease activity, instead 
of calculating new lesions. 
Additionally, the study can be conducted by utilizing the data from the 
current study for the detection of biological differences between: (1) HW-
treated patients with negative or positive disease activity (binary outcome); 
(2) HW-treated patients with reduction or stabilization of total lesion 
volume. 
 
7.2 Localised Grey Matter Atrophy in Multiple Sclerosis and 
Clinically Isolated Syndrome—A Coordinate-Based Meta-
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Analysis, Meta-Analysis of Networks, and Meta Regression of 
Voxel-Based Morphometry Studies 
GM atrophy regions involving the dorsal striatum, primary motor cortex, 
primary somatosensory cortex, insular cortex, auditory cortex and the 
relay station of the brain were identified cortically and subcortically in MS 
or CIS. The regions demonstrating significant effect sizes involved cortical 
and DGM regions, namely- bilateral Thalamus, Superior temporal gyrus 
(L), bilateral Putamen, Postcentral gyrus (L), Precentral gyrus (R) and 
Insula (R).  
Further, a network Meta-analysis has been conducted143, that works on 
the assumption that in case of the activation pattern reported by 
independent studies being consistent, the relative magnitude of these Z 
scores might also show consistency. 
The estimated statistical effect sizes may be important for powering 
prospective studies of GM atrophy in MS to test specific hypotheses and 
can be used as outcome measures of immunomodulatory or 
neuroprotective clinical trials. 
The strengths of this meta-analysis involve the utilization of ClusterZ 
algorithm, with the novelty of meta-regression. The use of standardized 
effect sizes makes meta-regression possible by looking for significant 
correlation between a specified covariate and the standardized effect size 
in each cluster. 
7.2.1 Limitations 
A well-done meta-analysis of badly designed studies is bound to yield 
invalid results. Primary studies dealing with bias and confounding might 
cause major problems for meta-analysis. In order to avoid the problem of 
including low quality studies, differences in study quality could have been 
explored by the meta-analysts. This could be done by applying sensitivity 
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analysis, by assessment of the effect of excluding studies with certain 
methodological weaknesses on the summary effect in the meta-analysis.  
 
7.3 Voxel-based morphometry 
Previous imaging studies conducted to assess the relationship between 
WM damage and GM atrophy have raised the concern of MS WM lesions 
having an effect on measures of GM volume by inducing voxel 
misclassification during intensity-based tissue segmentation.260  
Considering the bias that hypointense WM lesions can have on tissue 
segmentation, lesion masks can be created followed by lesion filling. 
Optimised VBM protocol247 can be adopted for the assessment of GM 
density alterations in MS. 
There are cases when normalization might result in the misinterpretation 
of structural differences, not directly related to GM or WM volumes, as 
volumetric differences. An example would be when the size of the 
ventricles differs significantly between two or more experimental groups. If 
the ventricles of one experimental group are enlarged during 
normalisation, the surrounding GM and WM also may be enlarged. This is 
because the parameters of the normalisation only encode highly smooth, 
low frequency deformations which may not distinguish between the 
ventricles and the surrounding tissue. As a result, structural differences 
pertaining to ventricular volume may show up in a VBM study of GM 
volumes. A way of minimizing this potential source of error is to perform 
the normalisation using the segmented GM and WM volumes rather than 
on the whole brain images. If all the data entering into the statistical 
analysis are only derived from GM, then any significant differences must 
be due to GM. The limitation of this approach, however, would be that the 
segmentation will be required to be performed on images in native space. 
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However the Bayesian priors, which encode a priori knowledge about the 
spatial distribution of different tissues in normal subjects, are in 
stereotactic space. A way of sidestepping this problem is to use an 
iterative version of segmentation and normalisation operators. First, the 
original structural MRI images in native space are segmented. The 
resulting GM an WM images are then spatially normalized to GM and WM 
templates respectively to derive the optimized normalisation parameters. 
These parameters are further applied to the original, whole-brain structural 
images in native space prior to a new segmentation. This procedure, also 
known as “optimized VBM”, will have the effect of reduction in the 
misinterpretation of significant differences relative to “standard VBM”.247  
FSL-SIENA261 can be employed, in combination with BEaST: Brain 
Extraction Based on Nonlocal Segmentation Technique262, to examine the 
longitudinal brain volume change over the course of intervention. 
The GLM also allows the identification of regions of GM concentration that 
are related to specified covariates. As a further research project, the 
relation of GM concentration to disease duration and age, that are 
statistically significant covariates as revealed by the CBMAN conducted, 
can be applied. 
The overarching hypothesis behind the thesis is that regional GM atrophy 
exists in MS or CIS, along with alterations in WM lesions. Although, the 
results of the Coordinate-Based Meta-Analysis, Meta-Analysis of 
Networks, and Meta Regression of Voxel-Based Morphometry Studies can 
be utlised for the development of a potential biomarker for 
neurodegeneration based on patterns of regional brain atrophy, the results 
from the VBM study could not be helpful due to the duration of the WIRMS 
clinical trial. However, future interventional trials (including possibly 
hookworm trials) may be designed prospectively to assess the effects of 
the intervention on the GM regions that we identified through our analysis 
to determine a potential neuroprotective effect. 
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Here, the recommendation refers to a further Phase 2 study to provide 
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